

EXHIBIT 7

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 358	Page 360
<p>1 Lebwohl-18, List of Search Terms, 2 was marked for identification.) 3 - - - 4 THE WITNESS: Thank you. 5 BY MR. MURPHY: 6 Q. And my question to you, Dr. 7 Lebwohl, is, if you were seeking to query 8 an adverse event database for suggestion 9 of sprue-like enteropathy and 10 olmesartan-associated enteropathy, would 11 you consider these search terms to be 12 adequate? 13 MR. SLATER: Objection. 14 You can answer. 15 THE WITNESS: I'm going to 16 look through the list and I'll ask 17 first for a clarification. Are 18 there items on here that I think 19 should be off or are there items 20 that are not on here that I think 21 should be on? 22 MR. MURPHY: With regard to 23 the items that are there, you can 24 first tell me whether there are</p>	<p>1 question I would ask certainly as 2 a researcher is, well, do we want 3 to maximize sensitivity or 4 specificity, do we want to capture 5 as many as possible and then worry 6 about weeding out others later, or 7 do we really only want to identify 8 the tip of the iceberg at the 9 beginning? 10 So I think that's an 11 important question at the 12 foundation. 13 BY MR. MURPHY: 14 Q. Assuming that we're beyond 15 tip of the iceberg. 16 A. If the question is do I want 17 to capture as many patients with 18 olmesartan enteropathy or this kind of 19 clinical phenotype as possible -- 20 Q. Yes. 21 A. -- then I would worry less 22 about being overly inclusive and add 23 others. I also would take issue with the 24 spelling and specific use of some of</p>
Page 359	Page 361
<p>1 any that you believe ought not be 2 on. 3 THE WITNESS: In terms of 4 the FDA looking for adverse events 5 associated with drugs? 6 MR. MURPHY: Well, not 7 necessarily FDA. I mean -- 8 THE WITNESS: Anyone. 9 MR. MURPHY: -- a researcher 10 like yourself who might be looking 11 into this question. 12 THE WITNESS: I think it 13 depends a bit on how sensitive 14 versus how specific one wants to 15 be. Is the question do you want 16 to cast the widest net possible so 17 that you can pick up early signals 18 or is the question that you want 19 to minimize noise and really only 20 focus on the signal, at which 21 point, we're sure to be missing 22 some patients with more atypical 23 or different kinds of signals? 24 So I think the first</p>	<p>1 these terms and I can go over these with 2 you if you'd like. 3 Q. Okay. 4 A. So, for example, abnormal 5 feces, certainly a feature, not a 6 necessary feature, but certainly a 7 feature. Feces can be spelled in two 8 different ways. 9 Change of bowel habit is one 10 way to put it, but change in bowel habit 11 is another; and, also, habit is often 12 plural, so I'd probably use a combination 13 Boolean expression to allow for all of 14 those. 15 Coeliac disease is one of 16 these conditions that has a few different 17 names; and so this one condition, the one 18 spelling is appropriate, but I would 19 consider also searching for it without 20 the O in the word celiac. With the O is 21 more of a British spelling. 22 I'd also consider celiac 23 sprue. I'd also consider gluten 24 sensitive enteropathy and I would also</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 362	Page 364
<p>1 consider nontropical sprue. These are 2 all terms that are interchangeable and 3 are used by different people to mean 4 really the same entity.</p> <p>5 Defecation urgency, I would 6 again consider spelling defecation 7 differently. The same goes for 8 diarrhea. There's an O in there and I 9 would consider taking it out as well.</p> <p>10 Enteritis, I don't take 11 issue with someone with olmesartan 12 enteropathy could have enteritis, but 13 what about enteropathy? I don't see it 14 here and I would certainly add it.</p> <p>15 Enterocolitis seems 16 appropriate given the enteropathy we know 17 is associated with olmesartan and also 18 the fact that many patients have 19 microscopic colitis.</p> <p>20 Fecal incontinence can be a 21 feature of olmesartan enteropathy, so I 22 would look for it with a mind that 23 there's more than one way to spell 24 fecal.</p>	<p>1 they might be misdiagnosed of having an 2 enteropathy due to diabetes as opposed to 3 olmesartan, so I would put it in there.</p> <p>4 Protein-losing 5 gastroenteropathy is a feature, not 6 necessarily the only feature, and I would 7 include that, same goes for 8 gastrointestinal inflammation. And 9 intestinal mucosal atrophy seems fine, 10 but I would include some others.</p> <p>11 Can I add what I think might 12 be helpful?</p> <p>13 Q. Yeah, please do.</p> <p>14 A. To start, microscopic 15 colitis, I think that's an important one 16 given that we know many patients with 17 olmesartan enteropathy share that 18 feature. And then I would use its 19 subtypes, lymphocytic colitis, 20 collagenous colitis.</p> <p>21 I would also consider using 22 collagenous sprue given that the first 23 time olmesartan enteropathy was reported 24 in the literature was in the context of</p>
Page 363	Page 365
<p>1 Frequent bowel movements is 2 -- it is what it is. Gastrointestinal 3 seems appropriate. Malabsorption, given 4 the caveats we discussed above, is a term 5 that I'm not crazy about, but if I want 6 to cast a wide net and I don't want to 7 just try to find the tip of the iceberg, 8 I would keep it in.</p> <p>9 Intestinal villi atrophy, I 10 think, is not a great way to search. I 11 would prefer intestinal villous atrophy 12 or just villous atrophy. Villous can be 13 spelled in a couple of different ways, 14 V-I-L-L-U-S and V-I-L-L-O-U-S. Welcome 15 to my world. Right?</p> <p>16 Fecal volume increased, 17 again, I would respell fecal.</p> <p>18 Gastrointestinal hypermotility is not 19 something that is commonly used, but it 20 seems appropriate.</p> <p>21 Diabetic enteropathy is 22 something that I would consider keeping 23 in simply because so many people who take 24 olmesartan happen to be diabetics and</p>	<p>1 that condition.</p> <p>2 Let's see if there are 3 others that I can continue to look for. 4 I think vomiting is an important one, 5 nausea, vomiting, diarrhea. I would 6 certainly look for that. Many patients 7 have those symptoms.</p> <p>8 I don't see abdominal pain. 9 I'm not sure why it was left off there, 10 but I would consider looking there.</p> <p>11 I would look for 12 specifically refractory celiac disease 13 because so many patients with olmesartan 14 enteropathy are initially misdiagnosed as 15 having refractory celiac disease.</p> <p>16 In that vein, I would 17 consider using those other terms that 18 have been used throughout the day, for 19 example, seronegative villous atrophy, 20 unclassified sprue, just sprue for short. 21 That would be another way to capture some 22 more.</p> <p>23 I think dehydration would be 24 an appropriate thing to look for and I</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

<p style="text-align: right;">Page 366</p> <p>1 don't see it on this list.</p> <p>2 I think if we want to cast a</p> <p>3 net and try to find as many as we can,</p> <p>4 those off the top of my head would be the</p> <p>5 list of search terms I'd start out by</p> <p>6 looking at, but it's very possible that</p> <p>7 there are some that don't come readily to</p> <p>8 mind that would also be manifestations,</p> <p>9 features of olmesartan enteropathy that I</p> <p>10 would include when doing my own search of</p> <p>11 associations with olmesartan.</p> <p>12 MR. MURPHY: I thank you for</p> <p>13 going through that and those are</p> <p>14 my questions, Doctor. I thank you</p> <p>15 for your time.</p> <p>16 THE WITNESS: Thank you.</p> <p>17 MR. SLATER: Okay. I just</p> <p>18 need a couple minutes and then</p> <p>19 we'll come back in.</p> <p>20 (A recess was taken from</p> <p>21 6:17 p.m. to 6:32 p.m.)</p> <p>22 - - -</p> <p>23 EXAMINATION</p> <p>24 - - -</p>	<p style="text-align: right;">Page 368</p> <p>1 Talley, T-A-L-L-Y (sic), I guess it is,</p> <p>2 about the -- what you cited there.</p> <p>3 And if you could, can you</p> <p>4 tell us what the quote is that you cite</p> <p>5 in your report and then tell us what the</p> <p>6 significance of that is from your</p> <p>7 perspective and why you added that into</p> <p>8 your report?</p> <p>9 A. Sure.</p> <p>10 Q. Or included that in your</p> <p>11 report, I should say?</p> <p>12 A. Sure. This was a commentary</p> <p>13 on the study by Basson and colleagues</p> <p>14 that we discussed earlier today and it's</p> <p>15 by Nicholas Talley, gastroenterologist,</p> <p>16 and it's published in the Annals of</p> <p>17 Internal Medicine.</p> <p>18 He writes, "The</p> <p>19 well-conducted database study by Basson</p> <p>20 and colleagues puts to bed any</p> <p>21 controversy surrounding the association</p> <p>22 between the ARB olmesartan and severe</p> <p>23 intestinal enteropathy pathologically</p> <p>24 resembling celiac disease."</p>
<p style="text-align: right;">Page 367</p> <p>1 BY MR. SLATER:</p> <p>2 Q. Doctor, you were asked</p> <p>3 during your testimony about presentations</p> <p>4 of olmesartan enteropathy less than one</p> <p>5 year after initiating the drug versus</p> <p>6 those after two years and were asked some</p> <p>7 questions about that earlier in the</p> <p>8 deposition.</p> <p>9 My question is this: Do you</p> <p>10 have an opinion as to whether or not the</p> <p>11 mechanism for why the person's symptoms</p> <p>12 are being generated would be any</p> <p>13 different where somebody's symptoms have</p> <p>14 an onset in less than a year versus those</p> <p>15 who are two or more years later?</p> <p>16 A. My opinion is that the</p> <p>17 mechanisms should be the same. They are</p> <p>18 the same regardless of the duration.</p> <p>19 Q. Looking at the last page of</p> <p>20 your report, if you have that nearby --</p> <p>21 A. Here it is.</p> <p>22 Q. -- you were asked a little</p> <p>23 bit about it and I think you wanted to</p> <p>24 just express something about the quote to</p>	<p style="text-align: right;">Page 369</p> <p>1 He goes on to say,</p> <p>2 "Evidence" surrounding "a causal relation</p> <p>3 now includes the strength of association,</p> <p>4 consistent findings, evidence of</p> <p>5 improvement in most patients after</p> <p>6 discontinuation, and relapse on drug</p> <p>7 reintroduction" --</p> <p>8 Q. I just want to stop you.</p> <p>9 You said "evidence surrounding"? Does it</p> <p>10 say "evidence supporting"?</p> <p>11 A. Forgive me. "Evidence</p> <p>12 supporting a causal relation." Then it</p> <p>13 goes on.</p> <p>14 Thank you.</p> <p>15 Q. And why is that of</p> <p>16 significance to you? Why did you include</p> <p>17 that in your report?</p> <p>18 A. I included it for a couple</p> <p>19 of reasons: One is, I think it provides</p> <p>20 a summation of the data that we have to</p> <p>21 date because it is recent and it</p> <p>22 incorporates some of the more recent data</p> <p>23 we have.</p> <p>24 But I also include it</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 370	Page 372
<p>1 because it's published in a high-impact 2 journal, by that, I mean high-reputation, 3 prestigious, often-cited journal, the 4 Annals of Internal Medicine, and the 5 language is clear that this issue has 6 really been laid to rest involving any 7 question about causality.</p> <p>8 Q. You were asked by counsel to 9 list those articles that state or -- and 10 you answered the question in the context 11 of stand for the proposition of the 12 causal relationship between olmesartan 13 and olmesartan enteropathy and you listed 14 a series of articles.</p> <p>15 If you were to go through 16 each article one by one, would you be 17 able to likely identify additional 18 articles?</p> <p>19 MR. MURPHY: Objection; 20 form.</p> <p>21 You may answer.</p> <p>22 THE WITNESS: I'm sure I 23 would identify additional articles 24 if I were to go through it again</p>	<p>1 the finding, do you have an opinion, and 2 if you can explain this, as to why that 3 is an important article in the overall 4 question of causation and how it fits 5 into the determination that you've given 6 of causation?</p> <p>7 A. A specific aspect of the --</p> <p>8 Q. You know what, I'm going to 9 withdraw that question, actually. I want 10 to ask you about something else, 11 actually. I want to ask you a completely 12 different question, actually.</p> <p>13 A. Okay.</p> <p>14 Q. I think you handled that one 15 for about an hour. I'm not going to go 16 back into it.</p> <p>17 Here's my question: You 18 were asked about the so-called hierarchy 19 of different types of studies, RCTs, all 20 those other type studies; and in the 21 context of olmesartan, in identifying and 22 studying the entity of olmesartan 23 enteropathy, can you just give us an 24 explanation of why it is or what your</p>
Page 371	Page 373
<p>1 that I didn't pick up the first 2 time.</p> <p>3 BY MR. SLATER:</p> <p>4 Q. In fact, on page 22 into 23, 5 you discuss an article by Schieppatti, 6 S-C-H-I-E-P-A-T-T-I, et al, and over to 7 page 23, you quote from that article: 8 "This study supports the causality of the 9 association between olmesartan and 10 enteropathy."</p> <p>11 Would that be an example of 12 an article you didn't list earlier, I 13 don't believe, that that would also stand 14 for the proposition? Is that an example 15 of that?</p> <p>16 MR. MURPHY: Objection to 17 form.</p> <p>18 THE WITNESS: That would be 19 another example.</p> <p>20 BY MR. SLATER:</p> <p>21 Q. You were asked about the 22 Greywoode article and I just want to be 23 very clear. Even though it did not 24 demonstrate statistical significance of</p>	<p>1 opinion is as to which studies have been 2 most helpful in understanding that entity 3 in the literature?</p> <p>4 MR. MURPHY: Objection to 5 form.</p> <p>6 You may answer.</p> <p>7 THE WITNESS: In fact, it's 8 the case reports with multiple 9 dechallenge and rechallenge in 10 multiple contexts from around the 11 world that are actually most 12 helpful.</p> <p>13 There are other study types 14 that we talked about earlier today 15 that have added to the impression, 16 but convincing case reports with 17 well-documented dechallenge and 18 rechallenge data can be the most 19 helpful, despite the fact that in 20 a generic pyramid of evidence, 21 case reports are on the bottom.</p> <p>22 In fact, RCTs are not well 23 suited to look at uncommon 24 long-term effects, both because</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 374	Page 376
<p>1 the number of patients in an RCT, 2 for example, the ROADMAP study, is 3 not sufficiently high so as to 4 look for an uncommon effect, nor 5 do they follow patients long 6 enough to look for a long-term 7 adverse effect.</p> <p>8 And I should add that even 9 within the ROADMAP study, it 10 turned out that there were 11 patients who had olmesartan 12 enteropathy which was not noted by 13 the authors of that post hoc 14 analysis.</p> <p>15 BY MR. SLATER: 16 Q. And when you say there were 17 patients that were noted that had that, 18 was that based on your review of internal 19 documents that were not publicly shared 20 with the medical community? 21 A. Yes. 22 MR. MURPHY: Objection to 23 form. 24 BY MR. SLATER:</p>	<p>1 stopping medication. Do you see that? 2 A. Yes. 3 Q. There's a plus sign next to 4 two of the patients which means that 5 improvement was seen; correct? 6 A. Just two of the patients? 7 Q. Yeah, if you look down, if 8 you go down that column for the 9 olmesartan patients, there's a plus sign 10 for two of them. Do you see that? 11 A. Perhaps you can show me. 12 Q. (Indicating.) In that 13 column (Indicating). 14 A. Oh, the biopsy column. 15 Q. Yes. 16 A. Yes, I see plus signs in two 17 of those patients. 18 Q. That means there was 19 improvement seen. 20 A. That's right. 21 Q. Not applicable is indicated 22 for the rest. Does that mean there just 23 wasn't a biopsy to look at at the time 24 this was published?</p>
Page 375	Page 377
<p>1 Q. You were asked about the 2 variable rates of resolution and timing 3 of resolution, et cetera, of olmesartan 4 enteropathy; and in terms of your 5 opinion, why is that with regard to 6 olmesartan enteropathy? 7 A. Why do I see that? 8 Q. Yeah. 9 A. It's analogous to variable 10 rates of healing we see in celiac disease 11 that include the individual's capacity to 12 heal that will vary from patient to 13 patient and we're likely seeing the same 14 phenomena, those patient-specific 15 variability, in olmesartan enteropathy.</p> <p>16 Q. Let's look at the DeGaetani 17 article for a moment. 18 A. Sure. I got it. 19 Q. Look, if you could, at table 20 3. I think that was the famous table 3 21 we've looked at a few times. 22 A. I see it. 23 Q. If we look at table 3, there 24 is a column for biopsy improvement after</p>	<p>1 A. That was my understanding, 2 that biopsies were not done. 3 Q. For those patients. Okay. 4 Now, with regard to that one 5 patient with the question mark in terms 6 of whether she had clinical improvement, 7 patient number 7 -- 8 A. Yes, I see that. 9 Q. -- during the course of 10 questioning by counsel, you had talked 11 about the fact that you thought it might 12 be that there was a lack of follow-up 13 data. 14 If you look at the 15 discussion section, below the discussion 16 at the bottom of the middle column, 17 there's a sentence that says, "Upon 18 discontinuation of this medication, all 19 15 patients on whom we had follow-up data 20 improved symptomatically, no longer 21 requiring immunosuppressive therapy if 22 they had previously been on it," et 23 cetera. 24 A. I see that.</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

<p style="text-align: right;">Page 378</p> <p>1 Q. So does that confirm for you 2 that there was a lack of follow-up data 3 on that one patient? 4 A. Correct. 5 Q. With regard to the Bradford 6 Hill criteria, did you consider the nine 7 different criteria as you evaluated the 8 evidence that was available to you in 9 forming your opinions in this case? 10 A. I considered those criteria 11 when I was evaluating the evidence. 12 Q. Even though you may not have 13 specifically named a few of them, it's 14 your testimony you did consider the 15 entire criteria? 16 A. Correct. 17 Q. And I think you mentioned a 18 few of the criteria during the course of 19 your testimony, like cessation of 20 exposure and others, those were criteria 21 you were aware of and applied? 22 A. Yes. 23 Q. In the Greywoode article, 24 there is a statement in the article</p>	<p style="text-align: right;">Page 380</p> <p>1 community rely on the information 2 companies provide regarding the risks, 3 for example, of medications that they 4 sell? 5 A. We do. 6 Q. And to the extent the 7 company has information internally about 8 risks, do you and other doctors expect 9 that that internal information is being 10 shared with you and others in the medical 11 community so you will have that in 12 treating and diagnosing patients? 13 A. Yes. 14 MR. MURPHY: Objection to 15 the form; lack of foundation. 16 THE WITNESS: Yes. 17 BY MR. SLATER: 18 Q. With regard to the internal 19 documents that you saw from Daiichi and 20 the deposition testimony you saw 21 regarding the adverse events they were 22 aware of and the internal discussions 23 about them, what was your reaction to 24 that when you saw that?</p>
<p style="text-align: right;">Page 379</p> <p>1 suggesting that milder presentations are 2 unlikely at that time. That's part of 3 the conclusion in the abstract? 4 A. Yes, it is. 5 Q. What's your opinion now at 6 this time and at the time you wrote your 7 report in this case as to whether it is 8 likely or unlikely that there are milder 9 presentations of olmesartan enteropathy? 10 MR. MURPHY: Objection; 11 form. 12 You may answer. 13 THE WITNESS: I believe that 14 milder presentations are, in fact, 15 likely. 16 BY MR. SLATER: 17 Q. Is that in part based upon 18 review of the literature and the case 19 reports that have been coming out even up 20 till very recent? 21 A. Correct. 22 Q. You were asked about 23 internal company documents. And do you 24 and other physicians in the medical</p>	<p style="text-align: right;">Page 381</p> <p>1 MR. MURPHY: Objection; 2 form. 3 THE WITNESS: Particularly 4 when I looked at the dates, I was 5 stunned by the dates, in that they 6 happened so far before the general 7 medical community was first 8 apprised of this condition. And I 9 would have loved to know about 10 those cases at the time that they 11 happened, well before the first 12 publications. 13 I think that my patients 14 would have wanted to and I think 15 that my group, the physicians in 16 the biomedical community, would 17 have wanted that information at 18 that time. 19 BY MR. SLATER: 20 Q. And why is that? 21 A. Given the morbidity that we 22 see in olmesartan enteropathy, the 23 suffering, the diagnostic travails that 24 many people have, the misdiagnosis,</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 382	Page 384
<p>1 there's hospitalizations and sometimes 2 even worse, if we had known about this 3 entity well before 2012, we could have 4 prevented a good amount of suffering. 5 Q. And you've seen the adverse 6 event reports and you were asked some 7 questions about them today. Even if 8 Daiichi had just shared information about 9 these symptoms that they were seeing and 10 the syndrome that they were seeing, even 11 if they didn't know what the name of it 12 was and just told doctors, we're seeing 13 multiple patients with these clinical 14 pictures, would that have been helpful to 15 you and of interest to you and other 16 physicians in your field? 17 MR. MURPHY: Objection to 18 form; lack of foundation. 19 THE WITNESS: For sure. 20 BY MR. SLATER: 21 Q. And is that for the same 22 reasons you just stated? 23 A. Yes. It also would have 24 helped our research efforts to better</p>	<p>1 nice weekend. 2 THE WITNESS: Thank you, 3 everybody. 4 (Witness excused.) 5 (Deposition concluded at 6 approximately 6:47 p.m.) 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p>
Page 383	Page 385
<p>1 understand this condition. 2 Q. You were asked at the end of 3 the deposition about search terms. And 4 in the interest of time, I'm just going 5 to ask you if the following terms would 6 also fall into the category of those you 7 would want to include if you were going 8 to cast this wide net to catch relevant 9 reports in the literature. 10 And in the interest of time, 11 I'm going to list them: sprue-like 12 symptoms, chronic diarrhea, abnormal loss 13 of weight, weight decreased, underweight, 14 anemia, renal insufficiency, renal 15 failure, and steatorrhea, would those be 16 helpful terms as well? 17 A. Yes. 18 MR. SLATER: I have no other 19 questions. 20 MR. MURPHY: I guess we're 21 done subject to resolution of our 22 request for the patient data that 23 I made earlier on the record. 24 MR. SLATER: Everyone have a</p>	<p>1 2 CERTIFICATE 3 4 5 I HEREBY CERTIFY that the 6 witness was duly sworn by me and that the 7 deposition is a true record of the 8 testimony given by the witness. 9 10 It was requested before 11 completion of the deposition that the 12 witness, BENJAMIN LEBWOHL, M.D., M.S., 13 have the opportunity to read and sign the 14 deposition transcript. 15 16 17 18 19 20 21 22 23 24</p> <hr/> <p>KIMBERLY A. CAHILL, a Federally Approved Registered Merit Reporter and Notary Public Dated: February 13, 2017</p> <p>(The foregoing certification of this transcript does not apply to any reproduction of the same by any means, unless under the direct control and/or supervision of the certifying reporter.)</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 386	
1	LAWYER'S NOTES
2	PAGE LINE
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	

--	--

Protected Information - Benjamin Lebwohl, M.D., M.S.

WORD INDEX				
< 0 >	318:6 385:15	208:24 209:20	43:14 44:12,	31 6:18
0.14 158:21	130 7:6 346:4	210:6 274:10,	15, 18 84:8, 14	335:12 347:3,
003790 340:18	14 4:16 29:9	14 276:17	335:12	10
05 6:22 7:3	138:6 155:15	2:20 199:13	2017 1:7	32 306:21, 22
160:7 230:12	320:11 337:9	2:33 199:13	97:23 385:15	307:19, 23
340:2 346:1	14th 332:4	20 222:2, 16,	20-pound	308:24 309:8
07068 2:4	339:16 340:23	19, 24 273:1, 3	319:13	320 6:12
07932 2:18	15 4:21 6:8,	274:13, 18	21 7:3 86:16	325 322:11
	12 28:10	275:13, 21	346:1	33 309:9
	218:13 307:9	276:1, 4, 14, 17	212 2:9	319:2, 3
	320:3 335:8,	277:15 311:3	215 2:14	335 6:16
	18 345:16	320:21	22 200:7	339 6:19
< 1 >	377:19	200 5:12	371:4	34 4:21
1 11:3, 8 35:3	15-2606 1:6	2000 2:13	228-9898 2:4	334:11, 12
92:21, 24	16 5:1, 1, 3	2005 339:16	22nd 319:7	335:22 336:5,
109:6 157:13	38:2, 2, 3	340:23 345:16	322:1	6, 8, 11, 17, 18,
158:10, 18	200:7 201:15,	351:17, 18	23 5:1 38:2	21
159:2 220:8	23 204:21, 23	2006 309:24	40:8 42:17	3400 1:16 2:8
276:10	205:2, 18, 21	310:2, 4 311:2	84:3, 8, 13	346 7:3
1.99 158:16	206:9, 21	2007 319:7	92:21 93:1	347 6:14
1:11 140:6	209:1, 19	322:1	96:15 371:4, 7	320:5
10 1:7 6:8, 8,	210:16, 17	2011 202:17,	23rd 39:4	35 5:1
12 8:11 256:7,	211:5 218:13	20 203:15	255 5:18	358 7:7
17 274:12, 18	220:9 243:17,	2012 18:6	26 4:21 34:12	35-year-old
307:9, 9 320:3	17 277:24	23:6 178:13	262 5:22	344:3
10:36 56:7	278:1 339:21	196:3 197:19,	27 147:6, 8, 9	36 339:9, 11
10:46 56:7	340:13 343:5	22 214:15	271 6:4	340:15 345:5,
100 243:9, 12,	160's 335:24	245:11 283:13	28 4:21	7 347:8
13, 19, 24	164 335:24	313:14 348:11	224:21 241:3	367 4:7
244:5, 5	17 5:1 35:23	355:23 382:3	250:24 254:10	36-year-old
10022 2:9	206:21 216:16,	2013 5:12	28th 39:8, 14	340:24
102 238:24	22 345:21	57:10 138:13	29 5:3 38:3	37 297:10, 11
103 2:3	173 337:2, 9	161:13 200:21	39:4 40:9	300:1
238:24	174 338:1	209:6 210:3	85:6	38 5:1
105 269:1, 5	178 5:10	214:11	2nd 2:3 332:2	
11 5:1, 3 6:12	18 5:1 38:2	2014 5:10, 22	< 3 >	< 4 >
38:2, 3 42:18	39:4 138:16	6:4 135:22	3 28:7, 16	4 29:9 34:9,
43:14 81:23,	155:17 357:21	140:22 178:24	43:19 158:15	19 35:8 36:8,
24 263:1	18th 2:13	262:15 269:24	161:13 205:14,	12, 15 81:14
320:3	40:8	271:8	17 210:4	180:10 275:13,
12 271:3	19 6:22 8:7	2015 5:18	218:12 375:20,	21 297:12
276:13, 17	98:17 340:2	28:21 29:9, 15,	20, 23	4:34 297:7
277:15 331:23	19103 2:14	21 30:6, 8	3.1 66:3	4:44 297:7
12:25 140:6	198 8:11	32:3 34:6	3:32 254:7	40 222:2
12:30 139:24	< 2 >	53:12 84:13	3:41 254:7	420 180:10
1239 267:12	2 5:1 14:6, 18	135:18 237:1,	30 37:19	43 47:2
129 6:24	35:3, 23 80:2,	6, 22 255:23	161:18 162:13,	44 37:17
340:3	22 81:7 89:9	310:3	14	46 8:7
13 307:17, 17	90:17, 23 91:1,	2016 6:18	307 6:8	< 5 >
308:5, 21	10 206:9	28:2 37:10		
		40:10 42:18		

Protected Information - Benjamin Lebwohl, M.D., M.S.

5 4:21, 21 28:10, 10 36:5, 8, 13 66:4 129:21 165:1, 2 177:13, 14 313:18 320:23 5.00 159:3 5:09 318:23 5:14 318:23 50 264:2 274:18 549-7000 2:19 58 345:16 58-year-old 347:1, 19 5th 28:21 97:23 < 6 > 6 37:23 38:20, 21 39:1 40:4 42:15 81:16 83:23 84:17 85:5 184:18 214:23 6:17 366:21 6:32 366:21 6:47 384:6 600 2:18 601 1:16 2:8 650 213:1, 9 < 7 > 7 6:22 38:9 88:24 92:5 158:9 161:8 199:18, 19 313:19 340:2 377:7 72 200:6 201:15 733 245:16 749 6:10 307:11 308:7, 10 79 159:2, 11 < 8 > 8 81:19 97:17 161:17 179:7 180:11 326:3	877.370.3377 1:22 88 5:5 < 9 > 9 4:5, 12 5:1, 1 7:3 35:23 38:2 134:5 276:1, 4 346:1 9:45 1:17 917.591.5672 1:22 95 158:14, 16 159:6, 8 973 2:4, 19 980-7400 2:9 988-2700 2:14 99 145:13 < A > a.m 1:17 56:7, 7 abated 319:19 abbreviated 257:2 abdominal 6:6 53:8 110:1 237:9, 10, 13 238:7 271:10 273:23 309:18 311:1, 13 312:11, 21 313:3, 5 314:5, 11, 17 315:10 365:8 ability 145:24 270:24 able 113:19 189:12 193:7, 11 199:3 231:14 242:22 313:20 338:10 370:17 abnormal 123:5 361:4 383:12 abnormalities 78:23 192:21 253:16, 20 290:3	abnormality 171:15 274:1 abouts 37:16 Abrams 93:19, 24 absence 60:4 111:3 170:3 245:2, 4 281:12 350:20 absolutely 280:21 absorb 119:6 absorption 259:18 Abstract 96:19, 22 97:3 113:13 267:14 270:16 273:20 302:10 379:3 abstractions 305:14 abundant 123:14 254:23 301:6 academia 270:22 accelerate 183:5 accelerated 342:18 accept 240:8 acceptance 335:3 accepted 108:18 160:5 262:8 access 16:9 329:24 accompanied 104:9 accompanies 86:9 Accompanying 11:10 account 94:15 100:17 243:2 294:22 accurate 22:11 274:7 314:16	accurately 15:23 156:12 196:13 264:14 297:23 accusing 161:20 achieve 160:8, 18 294:2 achieved 159:21 acid 265:17, 18 acknowledge 13:20 111:15 147:19 158:7 acknowledged 112:9 acknowledging 243:3 acknowledgmen t 336:24 acknowledgmen ts 335:2 acquainted 59:16 acronym 231:2 234:5 action 49:4, 20 50:11, 15 51:14, 23 53:1, 19 56:10 57:14 activation 259:12 active 192:1 234:1 activities 43:9, 12 activity 259:11 actual 36:21 162:9 269:17 278:13 acute 66:24 171:1 acutely 126:12 327:3 ADAM 2:3 27:13 82:9 105:15 131:10 235:9 add 56:8 60:1 113:15	157:13 196:4 229:23 259:9 269:15 360:22 362:14 364:11 374:8 added 368:7 373:15 addendum 35:11 36:6, 18 addition 12:11 additional 33:19 88:6 112:13 161:11 321:24 370:17, 23 address 49:20 63:16 88:9, 11 114:6 224:23 226:11, 12 227:6 addressed 44:3 51:15, 17 52:23 57:13 63:2 addresses 53:18 63:10 addressing 28:4 50:10 51:13, 23 292:11 297:14 299:19 adequate 358:12 adequately 230:18 233:24 adjusted 325:15 administrative 229:15 admit 163:8 adulthood 68:7 168:22 adults 222:14 223:5 advance 248:17 Adverse 6:21 58:18 66:23 148:18 149:13, 15 151:20 230:7, 17
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protected Information - Benjamin Lebwohl, M.D., M.S.

231:6, 12, 17	308:9 323:19	ambiguity	Annals 107:16	answered 44:7
233:4, 13	332:12	249:24	138:12 368:16	45:3 49:23
240:20 241:7	agreed 27:10	American 57:9	370:4	52:4 55:12
268:5, 16	233:12 334:20	amount 21:4	announcement	88:2 118:12
279:20 283:3	351:23	60:5 126:9	161:12 162:10	160:11, 13
286:18 303:4,	agreed-upon	223:10 259:13	Annual 96:18	172:16 205:1
11 304:8, 10,	125:14	269:16 382:4	Answer 8:5	233:8 241:24
17 306:4	agreement	Amy 3:2	10:8 13:19	253:10 296:9
334:19 337:17	125:5	analogies	16:6 20:4	342:20 370:10
339:15 340:1,	Ah 303:24	20:15	26:13 29:17	answering
22 345:14	ahead 26:4	analogizing	30:22 31:10	15:23 46:21
354:6, 13, 15,	38:22 94:20	122:14	36:11 45:4	108:3
24 355:14, 18	108:5 137:9	analogous	46:6, 19 47:16	antiarrhythmic
356:16, 17	259:2 292:18	67:21 103:14	48:4, 16 49:24	327:2, 4
358:8 359:4	325:12 353:15	121:21 176:14	52:9 56:9	anticipated
374:7 380:21	akin 261:15	291:7 296:16	57:18 63:6	284:12
382:5	al 5:17, 21	375:9	70:9 77:9	antihypertensiv
advice 29:19	6:8 18:1	analogy 226:3,	87:24 88:3	e 191:14
30:1 33:7	110:15 115:22,	9	89:21 90:5, 22	Antihypertensiv
63:23	24 201:1	analogy's	92:14 97:12	es 5:23
advised 16:8	256:2 271:13	290:5	106:22, 24	140:19 262:17
114:21 191:12	287:10 371:6	analyses 62:10	124:10 139:17,	apart 115:10
192:7	alarming	analysis 157:2	18 147:23	141:24
AERs 240:21	229:19	158:12 201:10	150:1 152:20	apologies
241:18 242:2	Al-Bawardy	224:16 225:6,	160:22 161:1	131:2 172:6
affect 127:16	97:16	18 231:21	172:14 173:2,	apologize
affirmatively	Alimentary	232:14 238:23	5, 18 174:6	117:14 120:1
47:21	135:16, 21	239:21 262:3	181:14 182:1	apparent
affirmed 9:8	allegation	353:20 374:14	190:11 192:3	169:4
affordable	23:23	analyze 240:15	193:13 194:11	appear 66:22
151:16	alleged 23:18	analyzing	203:4 207:4, 8,	67:3 127:22
African-American	25:15	247:20	17 208:7, 17	253:19 259:5
afternoon	Allen 80:19	anecdotal	215:7 216:6	APPEARANCE
173:3	84:4 323:15	284:13, 14	217:20 221:11	S 2:1
age 269:21	332:13	285:18, 20, 22	226:15 227:13	appeared
agent 143:1, 7	allergic 67:1	anecdotally	231:9, 14, 19	216:12 304:2
149:12 167:14	allow 65:20	284:1	234:9 235:6	326:4
176:22	288:20 296:5	anemia 119:9	236:4, 12	appears 34:20
agents 258:24	361:13	121:3 383:14	240:12 249:14	121:9 122:7
260:2	allowed 49:14	angiotensin	250:1 282:12	128:21 178:16
aggregate	allows 69:3	6:7 53:10	287:3 289:5	220:12 223:1
47:5 60:12, 17,	allusion 79:8	54:1 96:15	291:13 292:4	224:5 246:20
22 184:6	alternate	109:2, 14	294:10 296:11	256:23 260:16
aggregate,	257:15	110:3 153:11	302:8 310:12	280:9 288:12
60:15	alternative	237:14 251:9	313:16 314:10	313:6 331:15,
ago 24:20	79:12 317:23	258:5 271:12	324:21 331:7	22
60:10 303:3	318:4 326:9	angstrom	346:10 348:4	apples 247:6
agree 29:11	334:8 344:6	109:21	350:5 357:12	applicability
179:22 225:3	alternatives	animal 59:17,	358:14 370:21	261:22
244:9 284:23	317:20	19, 21, 23 60:1	373:6 379:12	
	amazing 188:8	animals 59:15		

Protected Information - Benjamin Lebwohl, M.D., M.S.

applicable 149:11 150:14 376:21	architectural 122:8	133:1 136:8, 9 137:3 138:24	341:7 356:24	assume 21:11 95:6, 8, 12
applied 333:21 354:21 378:21	architecture 123:22	140:9 151:24	asks 11:11, 19	114:11 250:4
applies 287:3	area 72:24	286:17 370:9, 14, 18, 23	aslater@mskf.n et 2:5	292:7
apply 230:8 385:18	87:3 141:1	ascertain 189:24	aspect 223:23 320:13 372:7	assumed 78:10
applying 332:22 333:17	areas 87:5	ascertainments 203:23	aspects 87:10 90:1	assuming 123:10 329:15, 18 337:3
appreciate 21:13 163:5 252:17 267:10	argue 59:18 133:9 154:9 185:14	aside 129:11 171:4 186:12	assess 315:19 317:18	352:2 360:14
appreciated 24:11	Arguellas-Gran de 110:4	asked 10:9 18:14 32:8	assessing 147:13 232:14	assumption 10:7
apprised 381:8	argumentative 234:17, 19 235:1	33:2, 7, 16, 21, 24 34:2 43:13	assessment 190:20 245:5 316:13 323:20 324:12	atrial 322:10 327:6, 8
approach 37:4	arm 230:8, 10 239:23	44:7, 21 45:3 47:18 49:23 64:9 77:12 88:1 102:24 118:7, 8	assessments 315:22 317:11	Atrophy 5:14 51:9 57:1 68:1, 3 109:16 119:20, 21 120:6, 8
approached 27:16 29:12, 19 30:1, 10 63:22 223:16	Article 6:4 19:5, 7 20:19 21:12 53:17 98:18 106:10 107:2, 10 109:7 110:21 111:21 112:10, 21 133:11 134:8, 13, 22 135:3, 5 137:1, 17 138:23 143:3, 11, 13 145:2, 4	130:12 136:9 141:2 151:23 155:20 160:10, 22 173:4, 6 174:13 194:4 207:9, 13 223:17 241:23 278:21 293:3 295:16 296:9 310:17 311:18 353:22 367:2, 6, 22 370:8 371:21 372:18 375:1 379:22 382:6 383:2	assistance 45:12, 21 Assistant 3:2 Associated 5:11, 20 41:24 42:1 75:3, 5 78:3 79:10 96:17 100:11 110:11 111:4 138:2 141:4 153:12 156:1 179:1 225:17 232:4 238:22 253:3 257:18 267:19, 22 268:4 322:16 323:2, 5 324:16 359:5 362:17	121:18 122:2, 6, 15, 19, 21 123:7 124:24 125:3, 8, 15, 20 133:24 134:7 136:3 170:2, 4, 10, 15, 19, 22 171:3, 9, 18 200:7, 22 201:17 204:9 205:8 214:8 247:23 252:2, 5, 23 255:12 350:21 363:9, 11, 12 364:9 365:19
appropriate 21:19 22:1 103:6 208:7 265:9 277:10, 11 302:20 361:18 362:16 363:3, 20 365:24	146:11 183:8 204:23 232:1 263:2, 7 267:12 271:8 305:22 370:16 371:5, 7, 12, 22 372:3 375:17 378:23, 24	375:1 379:22 382:6 383:2 asking 10:10 24:4 32:13 63:22 66:7 83:5 98:8 107:9 108:1 124:2 132:24 150:24 170:14 173:9 175:8 204:7 217:21 219:5 233:6 238:2 253:7 255:17 258:21 268:15 277:21 291:2 295:13 300:8 310:15	association 111:6 114:16 115:7, 12 129:5 158:20 159:9 160:2 161:1 227:6, 12, 17 228:2, 9 229:6 237:24 238:19 264:19 269:4 284:3 368:21 369:3 371:9	365:19
appropriately 290:11	articles 21:8, 9, 14 52:22 59:13 63:1 90:17 91:13 92:24 93:1, 15 95:20 99:18 103:7, 11 105:6, 10 107:12, 23 108:7 112:19 113:1, 10, 20 130:2, 10, 20 131:4 132:14		atrophied 93:22 attached 15:16 Attaching 6:22 7:4 340:2 346:3 attack 101:7, 8, 10 attempted 291:24 attempting 317:18 342:1 attention 47:1 79:16 114:22 137:8 165:14 166:5 205:13 212:24 224:21 254:10 274:10	
approved 1:18 301:3 385:14			associations 157:4 366:11	
approximately 296:1 384:6				
April 29:14, 21 196:3 197:19, 22 214:14				
apriori 248:3				
ARB 258:4, 4, 11, 14 259:14 273:14, 16 275:7, 9, 24 276:8, 13, 18 277:8, 16 368:22				
ARBs 229:16 267:18				

Protected Information - Benjamin Lebwohl, M.D., M.S.

319:2 334:10 335:7 attestations 25:3 attorney 9:17 13:15 24:24 30:9 attorneys 26:11 attribute 201:11 324:5 attributed 200:8 201:6 203:2 205:2 atypical 359:22 author 20:24 57:5 120:15 152:13 153:6 236:22 237:2, 17 authored 237:5 authors 78:13, 24 113:4 146:22 147:3 180:4 221:6 261:1 283:18 286:1 374:13 author's 57:6 autoimmunity 78:20 available 91:18 116:1 134:16 151:21 209:11 260:17 305:19 316:21 317:15 378:8 Avenue 1:16 2:8 aware 21:1 61:1, 3 63:17 82:7 93:23 94:23 95:15, 16 97:20 98:19 99:3, 8 137:4 170:20 221:16 228:22 298:18 299:2 300:20, 22 324:17 354:2	355:24 378:21 380:22 awareness 356:15 axes 100:19 253:13, 20 Aziz 133:4 153:18 155:19 Azor 191:21, 22 < B > B-12 282:7 back 19:15 35:4 36:24 42:5 48:20 54:10 55:6 66:12 70:14 86:13 90:5 94:1 98:21 106:6 113:2 118:10 139:15 152:5 169:1 171:21 173:3, 13 184:18 189:11 193:4 194:21 195:11, 17 197:5 199:14 208:20 212:22 215:17 249:18 254:10 277:23 292:10 303:8 311:23 316:23 318:17 321:21 324:14 339:3 351:18, 23 352:9 366:19 372:16 background 90:2, 12 95:5, 10 338:8 bad 126:15 292:17 barely 157:17 barrier 69:3 based 52:12 117:11, 16, 19 122:13 128:21 137:17 165:12 168:22 184:9 203:22 217:1	265:11 269:4, 18 279:4 282:16 288:23 306:7 316:21 318:10 331:24 332:11 333:3 334:18 343:22 374:18 379:17 baseline 277:9 basic 261:19 basically 187:24 190:16 basis 50:5 55:15 298:10 baskets 95:5, 14 Basson 75:17 112:14 114:5, 13, 14 115:16, 21, 24 132:1, 3 155:5, 6 227:7, 11, 15, 20 251:2 368:13, 19 Bates 347:3 bathing 258:23 bear 40:14 177:12 216:18 becoming 132:7 bed 368:20 beg 104:18 began 30:18 31:17 32:3 33:19 37:7 42:21 312:16 beginning 1:17 56:22 67:8 114:12 281:6 309:18 360:9 begins 165:6 199:23 278:5 behalf 23:12 32:5 behold 247:21 beings 60:6 259:17 belief 211:11 222:1 240:14	believe 12:8 14:3 19:13 21:7 30:5 35:10 37:9, 14 42:7 43:16, 22 47:18, 19 55:11 64:5 82:17 85:11 89:22 94:22 106:14 108:15 109:22 110:6 111:20 113:24 115:16 120:4 124:7 127:11 129:15 131:19 137:6 146:21 147:3 150:21 152:18 156:4 160:11, 13 173:6 174:4 191:20 196:3 197:18 204:15, 19 205:1, 3 210:6 211:24 212:19 213:22 216:8 221:1 222:6 233:18 236:14 239:1 253:6, 10 255:5 276:9 279:5 291:6 296:12, 24 309:1 310:14 324:10 343:18 350:15 359:1 371:13 379:13 believed 141:5 believes 25:23 belong 199:1 belongs 93:12 below , 240:21 beneficial 16:9 benefit 54:22 87:12 112:13 113:4 BENICAR 1:4 5:5 24:3 88:16 167:23 188:9, 9, 9, 11, 22 196:11, 23 198:4 216:12	320:22 326:2 332:1, 8 341:2, 20, 24 345:17 351:12, 18, 22 BENJAMIN 1:15 4:5, 14, 19, 23 5:8 9:4, 7 14:11 15:4 34:13 88:18 89:2 385:8 best 24:19 30:4, 11 32:2 33:6 37:19, 21 61:17 197:21 203:24 309:3 better 79:14 144:1 167:16, 22 171:3 175:18 185:23 186:21 187:5, 11 195:2, 8, 14 197:5 202:7 221:23 236:18 246:18, 23, 23 247:8, 10 248:5, 9, 10 285:8, 15 290:21 291:19 294:1 325:22 338:19 382:24 beyond 46:8 51:4 72:7 176:20 182:9 199:20 261:20 268:13 360:14 Bhagat 110:4 B-H-A-G-A-T 110:5 bias 149:7 BIDDLE 2:12, 17 big 95:5 biggest 277:2 bill 43:15 billed 40:19 41:8, 10 bills 85:18 binder 12:2, 5, 12 15:12 16:1, 2, 3 17:6, 11, 16 19:16
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protected Information - Benjamin Lebwohl, M.D., M.S.

20:17 21:14	blockers,	breakdown	285:16 318:16	74:18 75:11
56:19 137:16	53:10 110:3	69:2	327:24	77:18 79:2
bioequivalence	blood 191:13,	breeze 196:8	called 35:8	94:22 100:23
258:15	17 285:11, 12	BRENNAN	47:12 78:20	101:16 107:7
biologic 51:6	body 39:17	2:17	91:11 95:7	110:9, 15, 16
67:23	103:3	brief 25:3	100:10 295:14	112:13 122:5,
biological 49:7	bone 169:9	82:20 85:2	Campus 2:18	24 123:19
51:10 52:17	Boolean	297:3, 5	cancer 26:21,	128:5, 7, 23
227:3 254:14	361:13	bring 11:11,	24 261:12, 20	129:7 133:19,
255:1, 11	borne 120:8	20, 24 90:11	264:4	20 141:10
256:10, 12	122:7, 13	91:22	cancer-derived	142:5, 8, 12, 14,
biologist 59:3	127:8 349:13	bringing 33:19	261:18	15 144:5
biology 72:8	bottom 81:6,	brings 9:18	capacity 119:6	147:12 148:11,
biomedical	24 148:12	24:8 27:6	356:13 375:11	12 149:17, 18
381:16	150:11 165:5	British 361:21	capital 115:1	150:10, 10
biopsied	177:15 213:11,	broached	Capsules	152:16, 21
121:22 122:17	14 274:16	197:6	138:10	171:17 176:16,
biopsies 209:9,	278:4 306:23	broad 52:17	capture	18 183:20
10 210:7	307:22 308:24	55:17 117:22	150:19 264:12	185:16 186:2
257:11 377:2	334:15 345:8,	144:9	360:4, 17	193:3 208:24
biopsy 18:3	9 373:21	broadly 53:23	365:21	209:5 216:22
120:12 121:5,	377:16	55:14, 16	captured	217:2 218:8
16 122:19	boundaries	broke 141:1	228:14	222:6, 7
123:12, 14	144:2	brought 12:3	care 27:1	229:11 232:5
125:11 206:9	bouts 128:20	15:12 40:14	171:5 202:24	239:23 240:20,
207:12 209:1,	bowel 99:1, 5,	112:9 281:18	205:10, 11	21 241:7, 18
20 210:5	11 117:13	Budesonide	288:24	242:2, 14, 15,
273:3 278:10	119:4 261:15	138:10 183:2	cared 178:17	21, 21 243:7
318:7, 13	361:9, 10	192:13, 14	298:14	247:11 248:11
343:6, 8, 15, 17,	363:1	195:15, 17, 18	career 236:7	251:6, 16
18, 22 344:1	box 320:23	244:1 245:19	careful 126:4	259:6 261:16
375:24 376:14,	326:3 330:22	246:2	309:11	266:4, 5, 24
23	Bradford	bulk 63:8	carefully	270:10, 12
bit 36:21	224:16, 18, 24	Burbure	82:16 242:2	278:5 279:21,
112:20 127:7	225:5, 9, 17, 21,	133:12 153:20	cares 291:15,	21 281:17
211:4 212:10	23 226:4, 6, 17,	B-U-R-B-U-R-E	16, 16	282:22 283:6
244:18 263:7	19 227:1, 8	133:13	caring 284:20	284:17 286:10,
359:13 367:23	241:9, 12	< C >	Cartee 5:12	13 287:21
black 280:7	254:11 378:5	CACO 99:10	135:11 140:14,	288:12, 17
344:4, 10, 17	branded 211:1	260:19, 21	16 156:15, 16	289:24 291:3
353:17	Braunstein	220:20 221:6	179:2, 9 180:3	304:16 314:2
blank 37:8	110:4 131:18	Caco-2 260:21,	220:20 221:6	315:24 316:4
blinded 97:19	153:5, 9, 10	22 261:5, 7, 11	C-A-R-T-E-E	323:17, 18, 22
275:18	263:3 271:5	262:5	179:10	328:1 333:22
Block 39:11	break 56:3, 5	Cahill 1:17	Cartee-Murray	343:19 349:14,
blocker 258:5	140:1, 4	10:14 385:13	179:9 184:3, 5	14 353:16
blockers 6:8	156:13 194:17	calculated	case 13:1, 2	373:8, 16, 21
54:1 96:16	198:19 199:10	158:16 258:19	23:10 25:19,	378:9 379:7,
109:3, 14	253:24 254:2	call 119:15	22 26:1, 19, 20	18
153:11 237:15	297:5 318:15,	189:11 193:4	36:9 39:11	Case-Control
251:10 271:12	18		60:20 65:8, 21	6:2 109:17

Protected Information - Benjamin Lebwohl, M.D., M.S.

140:21 143:22	20 224:24	63:3, 12 69:18,	23 188:23	58:17 62:3
149:21 150:6,	297:22 300:6	20 77:8 78:22	189:3, 5, 7, 14,	72:11 73:16
18 151:3, 19	317:18 335:2,	103:9 107:24	16, 20, 23	89:24 97:2
152:3, 7 153:1,	4 336:24	108:8, 10, 15	190:2 196:14,	103:12 115:2
14, 16 154:19,	370:7 371:8	109:18 111:22	16 200:22	118:5, 24
24 155:7, 22	Causation	115:1 131:6	204:4, 5, 10	121:12 122:3
156:3, 15, 18	4:24 23:18	133:24 135:24	210:12, 20, 21	123:3 125:9
239:3 262:20	28:5 34:14	146:7, 15, 19,	211:7, 10, 12,	134:20 156:22
266:7, 13, 21	107:19 112:22	23 147:4	19, 21, 24	164:5 166:3
cases 33:24	115:8 130:10	152:1 157:1	212:5 228:19	170:24 177:1
43:5, 23, 24	132:21 133:7,	170:17 338:11	229:1, 3, 14	179:20 185:13
51:7, 9 72:12	10 139:3	causing 65:12,	248:7 257:19	188:24 204:18
137:11 143:17	140:10, 11	18 142:4	266:18 290:6,	223:14 244:4
169:18 171:1	142:24 163:16	144:8, 17	11 291:3	279:20 289:9,
172:17 195:8	316:12 317:11	166:22 216:12	296:17 343:19,	14 291:3
206:4 220:9	372:4, 6	222:8 332:24	20, 21, 24	300:24 303:8
222:10 230:12	causation's	334:21 337:14	344:4, 7, 11, 14,	304:16 315:16
264:21, 24	143:5	351:19	17 353:1, 4, 17,	331:8 333:21
265:5 266:9,	cause 23:19	caution	20 354:1	344:13 349:13
23 289:2	62:1, 22 68:1,	110:10 126:17	356:6, 7	350:24 352:11
305:15 316:22	11 69:12	cautious	361:20, 22	355:1 360:1
338:6 345:3	71:19 74:15,	110:22, 23	365:12, 15	361:5, 6
353:20, 24	24 77:23	111:18 162:8	368:24 375:10	362:14 365:6
381:10	79:14 103:13	250:18 276:6	cell 99:1, 4	certainty 47:8
Caspard	108:19 109:6	caveat 110:19	260:19 261:1	166:14, 21
81:16 86:6	111:12 112:1,	134:14 202:22	cells 99:10	167:9 172:21
353:21	5, 17 115:13	caveats 363:4	260:20, 22	174:2, 22
cast 144:9	134:6 139:11	Celiac 5:14	261:5, 7, 7, 16,	211:15
359:16 363:6	141:14 143:8	18:3 20:14	18 262:1, 5	CERTIFICAT
366:2 383:8	149:12 165:20	67:20, 22 68:4,	cellular 51:4	E 385:2
cataloged	166:1 176:15	9 73:5, 10	52:14 55:14	certification
355:21	192:19 205:7	74:1, 4, 8, 13,	center 250:16	385:17
cataloguing	222:18 223:12	16, 20 75:6, 9,	certain 11:12,	CERTIFY
356:3	230:15 239:13,	14, 18, 22 76:4,	20 20:15	385:5
catch 383:8	14 251:14	10, 13 77:8, 20	43:24 45:7	certifying
category	257:15 304:2	78:3, 11, 16, 17,	65:15 67:20	385:21
113:22 383:6	316:6 318:4	20, 21 79:2, 11	80:15 95:19	cervical
caught 289:17	323:5, 23	93:20 116:5	99:1 163:14	261:17, 20
causal 47:5	324:1 326:9	120:18 121:1	164:6 178:13	cessation
60:12, 21	332:14 334:6	122:14, 16, 21	180:5 212:16	193:1 246:24
68:13 92:1	351:12	123:4, 9, 15	216:1 217:5	254:22 378:19
216:24 315:19	cause, 103:14	125:10 164:10,	232:15 241:6,	cetera 91:19
317:5, 24	caused 23:24	22 167:21	18 255:8	146:16 281:13
369:2, 12	166:10 201:8,	168:4, 5, 9, 12,	280:12 307:2	282:7 375:3
370:12	14, 18 251:20	17, 19, 23	353:1 354:8,	377:23
causality 61:4	252:5, 19	169:13, 15	14 357:8	chalk 98:11
68:14 87:20	253:6 288:21	170:3, 16	certainly	125:23
107:19 110:9,	315:14	176:14, 17	20:11 25:5	chance 107:6
17 111:14	causes 48:13	177:8, 17	29:19 30:16	111:7 199:2
114:6, 8, 12	53:20 57:21	178:7, 9, 15, 19,	40:16 49:5	change 79:6
146:10 147:14,	59:14 61:22	21 180:6, 20,	50:1, 22 55:18	126:11 167:15

Protected Information - Benjamin Lebwohl, M.D., M.S.

171:11 325:21 328:12 361:9, 10 changed 325:16 changes 49:7 50:7, 19, 21 51:10 53:23 54:2 117:12 288:20 290:23 296:6 329:13 characteristics 100:6, 16 277:9 333:11 characterization 243:16 characterize 111:17 119:18 201:22 227:22 244:5 245:1 246:14 276:10 279:24 characterized 202:19 203:22 218:17 355:21 characterizes 244:15 characterizing 281:7 317:24 charged 82:13 chart 134:9 185:8 186:6 209:17, 19, 23 charts 184:22 188:8 196:1, 6 197:20 198:13, 24 203:1 349:1, 22 check 26:5 115:18 152:21 161:24 169:9 209:6 211:3 330:21 353:6 checked 115:6 checking 340:17 chemokines 51:4 Cherry 2:13 chest 101:9 child 168:20	choice 240:1, 10 chose 129:8 246:13, 16 265:4 Chronic 5:23 128:11, 19, 23 136:15 137:21 140:19 238:1, 7, 20, 23 239:11 262:17 383:12 chronology 203:5 CIOMS 7:5 346:3 circumscribed 317:1 circumspect 110:7, 19 circumstances 122:18 172:24 284:20 285:1 cite 21:3 146:6 149:16 177:10 200:12 227:7, 15 251:2, 5, 15 254:15, 19 255:15 256:12 278:10 334:24 335:22 336:4, 22 339:18 368:4 cited 94:12 154:12 163:11 217:23 305:17 368:2 Civil 1:4 Claiming 234:20 claims 229:15 claims-based 242:13 clarification 24:10 217:22 358:17 clarifications 327:15 clarifies 265:21	clarify 19:23 24:4 37:2 38:19 52:10 60:18 84:12 88:10 207:4 219:13 239:2 clarifying 207:7 classically 154:23 classification 116:10 266:2 classified 203:10 233:10 clear 17:7 32:18 51:21 52:6 53:16 85:17 90:9 130:1, 11 138:24 140:23 148:21 178:12 179:23 235:5, 8 244:13 261:24 277:15 286:4 303:13 308:20 355:3 370:5 371:23 clearly 43:10 68:10 169:6 176:16, 17 188:22 271:1 285:9 312:11 350:13 Clinic 140:22 180:6, 19 183:23 184:6, 14 185:17 186:13 231:23 clinical 16:24 50:3, 17, 20 53:11 57:22 58:11, 16 59:5 60:4 62:3 69:22 72:17 73:17 87:10 90:1 100:16, 20 101:12 111:3 116:23 117:10, 24 119:19 120:20 121:1 123:20	126:18 127:23 129:9, 18 136:16 141:16, 18 165:13 167:12 175:14 176:6, 9 177:20 183:3 187:1 205:21, 24 206:5 218:13 220:11 223:14 230:5 231:3 239:8 241:13 243:18 244:16, 24 246:21 250:12 252:21 253:8, 14 255:6 257:5 280:8 288:23 289:2 290:2, 12, 19, 20, 24 291:17 293:10 296:21 298:11, 13, 15 305:9, 10 306:5 323:10 325:7 333:12, 16 349:19 352:18 354:19 360:19 377:6 382:13 clinically 78:6 202:4 206:19 245:18 280:10 291:9, 20 293:13 clinicians 20:21 clinician's 211:11 clinicopathologi c 58:9 Clinic's 145:5 close 305:15 308:14 338:17 closed 46:2 closely 75:23 82:16 211:4 232:18 code 116:11 coded 326:3	codes 116:2 357:15, 18 Coeliac 361:15 cofactor 67:6, 12 69:7 72:6 cofactors 69:14, 15 coherence 226:11, 16, 21 coherent 229:12 250:3 cohort 149:21 150:5, 18 151:2, 12, 18 152:19 154:7 155:8 227:21, 23 242:24 266:13, 14 colitis 362:19 364:15, 19, 20 collaborate 164:14 collaborated 164:11 collaboration 151:6 collaborations 164:23 Collagenous 97:17 129:13 364:20, 22 collated 304:19 colleague 93:23 colleagues 56:16 65:22 66:1 75:17 93:19 94:8, 22 97:16 98:4, 18 109:12 112:14 113:2 114:14 115:16 128:13 133:5, 12 135:13, 18 136:14, 20 137:10, 20 138:1, 9 140:18 144:4 145:4 146:3 155:3, 24 184:22 187:23
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protected Information - Benjamin Lebwohl, M.D., M.S.

196:8, 22	coming 186:12	316:13 379:23	component	13 332:24
198:3 202:7	251:7 332:23	380:7	166:7 224:17	379:3
204:7 232:2	350:11 379:19	comparative	components	conclusions
248:2 268:8	comment	97:18	69:4	146:1
273:1 287:4	78:13 94:14	compare	comprised	concomitant
368:13, 20	207:10 329:23	222:2 248:15	40:5	313:2 343:20
collected	commentary	273:5 277:10	computer 37:8	concrete 43:7
200:5 204:11	103:18 368:12	compared 6:7	357:4	48:6 190:11
collection	commented	53:9 70:3	conceived	condition
60:22	229:22	110:2 159:12	203:7	48:13 87:11
colloquially	commenting	192:16 212:7	concentration	100:4 117:4
59:7 101:8	154:6	237:14 248:1	258:17 260:4,	119:21 165:11,
colon 26:21,	common	257:6 258:3	7	12 169:17
23 261:12	116:22 117:1,	263:15 271:11	concentrations	177:5, 16
264:3	2 118:3, 4, 17	273:1, 6	259:4, 21, 24	183:19 186:14,
colonic 261:11	119:22 120:1	comparing	260:12	15, 16 201:18
262:1	121:19 124:3,	71:13 276:7	concern 344:20	202:16 240:17
colonoscopies	18 128:1	comparison	concerned	245:1 251:20
26:22	141:3, 4 145:9,	260:1	230:4 304:3	252:8 253:1
colonoscopy	23 159:6	comparisons	concerning	354:1 355:20
157:17 263:15,	162:4 185:1	258:7, 9, 11	229:7	361:17 365:1
21, 24 264:2, 4,	210:21 239:13,	compatible	conclude	381:8 383:1
22 265:3, 8	18 241:16	121:12 289:9,	107:23 111:24	conditions
Columbia	263:13 265:15	12 350:24	139:1 144:18	55:23 177:3
235:23 236:7	267:6, 8 274:4	compelling	151:24 196:12	211:9 306:7
292:16	279:6 280:16	103:24 166:5	concluded	361:16
column	312:23 322:16,	285:19	79:1, 4 101:23	conduct 58:23
206:15 213:8,	23 324:15, 18	complained	141:13 142:3	286:2
12 277:3	325:2 327:23	141:12	196:15 201:16,	conducted
375:24 376:8,	commonly	complaints	20 203:12	50:9, 12, 22
13, 14 377:16	118:1 127:3	347:22 348:2	273:20 384:5	51:13, 22
columns	192:13 280:13	complement	concludes	52:24 53:19
157:13 206:14,	317:17 363:19	212:3	111:21	235:23 333:4
16, 17	communicated	complemented	concluding	334:1
combination	27:13	87:8	146:6 317:4	conferences
191:20 338:5	communication	complete	conclusion	58:9
361:12	12:16 229:8	35:15 37:12	22:15 47:3	confidence
come 20:23	communication	137:15	60:8 87:14, 19	158:5, 14, 17
42:5 53:14	s 32:14 45:6	completed	89:15, 16, 18	159:1, 7, 8
75:12 79:12	163:2 298:19	37:20 94:24	103:4, 8	confident
91:23 93:9	community	303:7	108:20 111:9	24:22 96:1
141:21, 23	64:24 113:17	completely	112:3, 12	212:4 270:12
171:7 183:22	121:9 177:23	372:11	113:15 114:7	confidential
185:18 204:10	374:20 380:1,	completeness	129:4 131:5	299:9
239:19 240:10	11 381:7, 16	177:21	135:23 138:23	confirm 308:2
299:21 306:11	companies	completion	139:11 140:11	346:17 348:15
339:3 366:7,	380:2	385:8	144:21, 22, 22	378:1
19	company 82:4	complication	146:13, 18	confirmed
comes 142:10	298:1, 20	114:21	156:23 185:11	186:18
145:17 190:19	299:10, 16	complies	186:8 267:11,	confirming
191:20 293:17	301:2, 9 307:2	216:17		25:4

Protected Information - Benjamin Lebwohl, M.D., M.S.

confused 336:17	consultation 14:2	controls 155:6 263:16 264:21	160:23 162:17 164:1 169:21	378:4, 16 379:21
confusion 215:18	consulting 39:10	265:6, 19 267:1 273:7,	171:14, 24 174:10 178:7,	correctly 10:22 348:14
congruence 328:16	Contact 6:22 340:1	12, 24 274:20, 24 275:12, 22	15 179:19 183:12 185:12	349:8
congruent 87:2	contacted 30:8 188:13 190:9	276:12, 17 277:6	186:9 193:8 195:4 197:20	correlate 232:17 291:1
connection 246:5 256:9	196:17	controls, 274:5	200:13, 14	296:20
consequence 158:23	contemplating 57:20	controversy 368:21	205:8, 18, 23 206:11 209:22	correlated 159:4
conservative 111:18	contend 31:20 336:23	conversation 24:24 27:21	210:13 211:9 213:19 214:11	correlates 229:10 340:18
consider 30:24 111:11 118:24	Contents 56:21, 23 80:5	187:7 195:20 215:2, 23	215:21 217:9 221:9 224:16	correlation 115:8 156:20
119:13 123:23 294:20 351:7	context 262:7 290:10 301:12,	conversations 32:20 33:14	225:1 227:9 228:19 231:7	229:4
358:11 361:19, 22, 23 362:1, 6,	19, 22 302:3, 14, 21 304:18	36:24	232:12 233:14 236:1 241:20	correspond 164:13, 20
9 363:22 364:21 365:10,	305:23 306:3 338:19 345:1	convey 130:24	243:10, 14 244:7 247:4	corresponds 308:2
17 378:6, 14	364:24 370:10 372:21	convincing 60:20 61:24	249:7 251:4, 21 252:19	corticosteroid 183:3
considerable 278:6	contexts 373:10	62:15 110:8 123:19 168:2	254:18 256:10 258:4, 9 261:3,	corticosteroids 247:9
consideration 225:5	continue 130:1 365:3	197:3 242:17 373:16	9 263:4, 5 267:12, 21	cost 41:24
considered 128:10 194:5,	continued 326:2, 24	copy 12:13 105:8 179:8	271:21 272:22 274:6, 13, 22	Counsel 3:2
7 247:14 281:11 334:9	332:8	Correct 12:22 15:16, 17	275:15 276:3, 15, 16, 23	11:5 12:17
378:10	continuous 294:15	26:18 29:6, 7, 9, 10, 15 31:8	277:18 278:11, 16, 17 279:11	13:10 14:2, 19,
consistency 240:19 241:9,	contrary 61:1 108:14	32:6 39:3, 5 40:5, 6, 9, 10	292:13 294:8 295:9, 15	23 24:3 32:21
12, 18	contrast 176:9	42:3, 4 47:10, 11 53:21	297:24 300:18 308:6, 8 309:7	46:21 198:10
consistent 369:4	control 152:16, 21 154:22	57:15 58:4 61:16, 18	313:14 314:7 316:7, 9	300:18 370:8
consistently 356:4, 12	183:4 239:24 265:15 266:4	65:10, 18 80:16, 17	319:13 321:21 322:2 323:24	377:10
constipation 127:12, 18	273:3, 15 275:7, 9	81:17, 21 82:1, 2 83:8 84:5,	324:8 328:5, 8 329:16, 19	count 191:24
128:3, 6, 20 278:8, 15, 20,	276:22 277:11 385:20	21 86:1, 2, 4, 7 89:13 90:20	331:5 332:20 337:1, 20	236:14 270:16,
24 279:7, 7, 9 324:18	controlled 63:16, 19	95:23 100:14 101:4 115:23	340:16 341:3, 20 342:2	23
constitute 36:9	148:10, 23 150:22 151:14	118:19 131:17 137:5 146:8, 9	347:1, 19, 23 348:2 355:5,	country 189:21 264:6
constitutes 17:11 90:16	256:19, 21 260:13 284:19,	147:17 149:22 159:16, 21	19 376:5	couple 9:21
constrained 270:20	24 285:17			30:6 104:6
consult 163:19				114:18 140:8,
				23 141:2
				307:4 309:16
				363:13 366:18
				369:18
				course 17:3, 5,
				5 27:22 64:2,
				13, 14, 21 65:5,
				7, 9, 13, 15
				70:12 90:2
				95:11 99:14
				112:12 142:6
				165:13 175:16,

Protected Information - Benjamin Lebwohl, M.D., M.S.

20 194:12	190:21 201:21	296:22 316:18,	251:18	deficiencies
226:4 261:18	cultures 59:9	21, 23 317:1, 1,	deal 238:3	117:17
285:4 290:16	cumulative	15 324:11	dealing 217:23	deficiency
300:11 302:12	67:4 221:22	325:23 329:10	deals 232:11	119:9 121:3
325:16 329:20	curious 13:22	369:20, 22	dealt 303:21	define 175:6, 9
377:9 378:18	current 25:7	373:18 377:13,	death 173:4	316:3
COURT 1:1	239:7	19 378:2	decades 151:13	defined 117:8,
48:22 55:8	curse 95:7	383:22	December 23:6	22 124:21
66:14 70:17	99:12	database	deceptive	126:5 128:8
173:12 249:20	cut 208:7, 16	120:20, 22	233:19	168:13 221:23
312:7	cutaneous	354:3, 5, 7, 13,	dechallenge	278:6
covered 156:8	138:2	17 355:4, 8, 14,	142:16 165:15	definite
cradle 151:9	cutoff 160:5	18 356:16	166:9, 15	315:21 318:2
Crawford	175:20	357:9 358:8	167:1, 5, 11, 13,	definitely
81:20	cytokines 51:3	368:19	20 168:2	303:22
crazy 363:5		date 1:17	172:1, 12, 19	definition
created	< D >	28:1, 21 29:8	173:17, 21	227:24 246:16
301:13, 16, 17	Daiichi 2:15,	37:18, 20 53:4,	174:10, 17, 24	247:8 250:5
creation 302:4	20 3:3 9:17	12 84:6 97:23	175:2, 10, 17	266:8 295:10,
criteria 77:19,	82:3 136:7	196:3 202:11	203:5 217:2	21 298:7
22 78:4 128:9	297:18 300:21	302:16 309:23	242:19 254:24	definitions
184:12 224:18,	323:17 345:15	310:1, 4	283:15 288:5	101:15 125:4
24 225:9, 21	353:3 356:2	330:19 351:16	289:10 295:11	127:6 333:14
226:5, 6, 10, 17,	380:19 382:8	369:21	319:17 326:11	definitive
20 227:1	Daiichi-Sankyo	dated 39:3	329:9 373:9,	167:4, 17
241:12 246:9,	319:7 339:16	42:16, 16, 18	17	173:21 174:9,
11 247:16	340:22	85:6 385:15	dechallenged	12, 14, 16, 17
248:14 253:18	daily 294:19	dates 29:5	200:3 291:10	175:2 203:4
254:11, 21	295:1 322:12	40:7 381:4, 5	dechallenges	definitively
257:14 313:23	damage 67:4	daunting 37:7	293:22 345:2	152:20 166:1,
333:16 378:6,	304:3	day 16:11	decided 77:5	9 172:9
7, 10, 15, 18, 20	Daniel 102:6	32:19 37:15,	decisions 298:4	240:13
criterion 78:5	dark 351:21	16 59:10, 10	deck 248:17	DeGaetani
183:16 225:12,	data 60:4, 6,	102:4 157:22	declared	5:17 56:15
14, 16, 22	23 61:1 113:5	176:6, 8 198:1	117:16	57:6 132:16
226:11 227:9	115:24 145:19	240:3 253:11	decreased	153:15 200:12,
240:18 241:9,	151:21 167:5	294:24 311:4	383:13	17, 24 204:1
20 245:14	173:22 174:24	365:18	deemed	205:13 218:4,
250:23 251:4	203:5 205:17	days 116:14	218:22 230:14	6, 12 243:11
254:14 255:1	209:18 210:5	170:1 251:23	deep 59:22	248:13 375:16
256:23 348:16	218:12 221:22	252:18 293:16,	deeply 59:16	degree 47:8
criticism 151:1	228:3, 5, 7, 15	19, 22 331:23	88:9	83:20 143:16
cropped 186:2	229:16 230:24	350:18	Defecation	166:13, 21
cross-sectional	231:1, 5	day's 39:20	362:5, 6	167:8 172:20
97:18	232:12, 14	day-to-day	defendant	174:1, 21
cry 325:6	233:9, 10, 12	58:11 298:10	23:13, 15	206:5 239:6
crypt 123:24	239:21 240:2,	305:10	Defendants	242:18 244:13
CSPV 334:18	15 242:13, 20	de 133:19	4:17 9:18	245:3 331:11
CSPV's 335:3	246:21 247:21	154:13	14:10 15:3	degrees 93:21
culprit 145:10	254:24 282:18	deafening	61:9, 14	122:8
	291:5 293:17			

Protected Information - Benjamin Lebwohl, M.D., M.S.

dehydration 51:8 284:7 319:12 320:22 332:3 334:22 337:15 347:23 350:20, 24 365:23	41:12 77:14 80:15 81:20 82:1 84:4, 11, 20 85:9, 21 88:14 89:1 91:14 96:24 101:22 102:3, 5, 16, 18, 20, 21 178:23 179:8 200:20 255:22 262:14 263:1, 9 271:7 307:8 308:6, 12, 14 320:2, 12 335:1, 10, 12, 19, 20, 21 336:18, 23 339:23 345:24 357:24 367:8 380:20 383:3 384:5 385:6, 8, 9	describing 184:10 263:11 278:7 DESCRIPTIO N 4:12 29:5 129:19 211:5 239:7 281:17 320:19 design 144:19 145:18 202:23 266:19 designed 63:20 157:21 231:11 233:23 239:3 247:18 designer 56:14 designing 63:23 designs 239:20 desk 316:19 325:3 desperate 197:1 despite 323:13 342:4 373:19 detail 93:11 details 25:20 338:7 detect 233:24 270:8 detected 158:19 270:3 determination 324:9 338:11 372:5 determine 17:9 33:1 205:7 263:12 281:23 292:1 316:6 determined 143:7 202:12 214:2 develop 67:22 69:8, 15 76:5 developed 96:20 97:3 253:18 340:24 developing 68:19 97:5 342:15	development 72:5 150:20 280:21 develops 70:4 76:9 diabetes 364:2 Diabetic 363:21 diabetics 363:24 diagnose 118:21 120:3 126:23 290:9 306:6 diagnosed 73:20 74:20 117:3 119:23 165:12 168:17, 19 169:13 184:14 196:14 248:6 343:22 diagnoses 211:1 229:15 diagnosing 306:9 380:12 diagnosis 26:24 50:17 64:22 72:19 73:8 78:22 100:17 120:18 124:4 168:14 172:21 180:16 189:4, 6 210:12 212:20, 21 214:11, 13 228:13 306:13 315:13 316:9, 11, 15, 17 317:3, 13, 16 318:3 332:23 333:4, 13, 21 334:2, 4 343:24 350:21 353:18 357:15, 18 Diagnostic 5:15 57:3 78:1 200:23 257:17 381:23 diagrams 212:13	Diarrhea 5:24 51:8 119:1, 15 120:11 121:2 126:21, 22 127:2, 6, 9 128:1, 11, 19, 24 137:21 140:20 143:22 144:8, 11, 17 145:9 157:5 159:10 160:3 183:4 238:1, 8, 16, 17, 20, 23 239:11 262:18 263:14 264:8, 20 265:1, 2, 4, 10, 16 266:10, 17, 24 267:19, 23 268:23 278:9, 16, 19 279:6, 10, 14 280:14 312:15, 24 313:10, 11 314:6, 13, 18 315:9 319:12 320:21 325:5 326:1, 3 330:13 332:3, 7 334:22 337:15 341:1, 19 348:2, 7, 12, 13, 15, 18, 23 349:3, 5, 12, 17 350:3, 7, 12 351:22 362:8 365:5 383:12 Diarrhea, 136:15 diarrheal 111:10 288:21 296:6 dictated 246:11 dies 166:18 diet 78:15 168:21 180:22 197:7, 15 211:14 212:7 281:2, 5, 10, 15 290:10 342:11
------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protected Information - Benjamin Lebwohl, M.D., M.S.

dieting 342:1, 4, 6, 9	219:17 224:20	220:21, 23	210:12, 20, 21	divulging 25:21
differ 277:8	235:8 274:9	233:11 240:22	211:8, 10, 12,	Doctor 14:17
difference 247:2, 5	297:9 334:10	272:24 278:5	20, 22 212:1, 5	34:18 35:6
266:12 291:8	335:6 385:20	280:24 298:13	228:19 229:1,	38:8 45:11, 11
differences	directing 319:1	305:21 363:4	3, 14 245:5	64:12 69:17
72:2, 9 259:1	Direction 8:5	368:14	248:7 257:19	72:13, 13
273:22 276:9	directly 19:17,	discusses	266:18 290:7,	88:23 106:12
different	22 20:7, 8	299:7 319:11	11 291:3	125:18, 22
27:15 69:19	45:8 234:14	discussing	296:18 342:11	177:5 179:6,
73:22 100:19	276:7 306:19	43:23 50:15	343:19, 21, 21,	15 199:17
117:9, 9	disagree	68:14 198:2	24 344:4, 7, 11,	205:13 207:1
125:12 126:1	243:23 316:16	220:19 292:23	14, 18 353:1, 4,	208:19 217:15
144:14 170:8	discharge	discussion	18 354:1, 5	221:16 230:23
171:14 246:7,	284:8	22:6 43:5	356:6, 7, 10	235:22 252:15
8 247:3 248:1,	disclosed 13:3	87:7 94:4	361:15 365:12,	254:9 256:6
14 249:6	discontinuation	207:24 213:3,	15 368:24	262:24 268:7
251:13 253:13	78:6 183:17	7 284:16	375:10	282:23 288:18
257:4 258:6	195:3 202:8	307:19 377:15,	diseases 111:4	297:9 298:18
333:16 353:11	246:2 281:22	15	116:11 261:22	299:16 304:13
359:23 361:8,	282:1, 14	discussions	262:7 343:20	306:20 307:16
16 362:3	287:12, 17, 19	380:22	dismiss 285:18	308:20 310:9
363:13 367:13	295:22 326:17	disease 18:3	disorders 75:2,	317:9 319:1
372:12, 19	369:6 377:18	20:14 67:20,	5 78:2 79:10	320:10 321:21
378:7	discontinue	22 68:4, 10	177:19 257:18	335:17 340:12
differential	168:11 191:12	73:6, 11 74:1,	disparaging	345:5 366:14
306:13 316:8,	192:8 201:24	4, 9, 14, 16, 21	284:15	367:2
10, 15, 17	discontinued	75:6, 9, 15, 18,	disparities	doctors 73:14
317:3, 13, 16	186:22 187:6	22 76:5, 10, 13	18:2 120:18	188:4 243:23
318:3 332:23	206:11 215:5	77:8 78:4, 11,	dispute 61:4	380:8 382:12
333:4, 12, 18,	216:3 217:9,	17, 17, 21 79:2,	99:9 181:6, 7	doctor's 13:23
20 334:1, 4	18 218:10	11 93:20 99:1,	disrespect	Document 5:5
351:5	282:6 295:8	5, 11 116:6	164:12 193:12	13:7 14:18
differently	326:19, 22	120:19 121:2,	disseminated	15:7, 10 29:4
37:5 125:12	328:5, 8	21 122:14, 16,	230:19 352:11	80:23 85:8
245:3 362:7	331:12 332:2	22 123:4, 9, 16	dissemination	88:15 89:3
difficult 10:14	discontinuing	125:10 164:10,	310:6, 7	233:1, 3, 6, 7
189:24 197:15	209:2, 22	22 167:21	dissolving	300:9 301:15,
298:17	discovered	168:4, 5, 9, 12,	259:18	16 302:2, 4, 16
Dilemma 5:16	201:13 203:11	18, 19, 23	distinct 211:9	310:18 311:16
57:4 200:24	246:5	169:13, 16	distortion	312:19 320:13
diminish	discovering	170:3, 16	122:9	321:13, 19
149:7, 17	196:10	176:15, 17	distressing	328:3, 3, 10
dimly 95:16	discrete 175:21	177:8, 18	350:11	330:5, 10
dinner 235:17	discuss 243:8	178:7, 9, 15, 19,	distributed	331:10 343:13
dire 195:19	261:1 286:19	21 180:6, 20,	250:15	documented
direct 79:16	295:7 340:14	23 188:23	DISTRICT	78:19 312:12
129:20 147:7	371:5	189:3, 5, 7, 14,	1:1, 2	313:8
158:23 177:11	discussed	16, 20, 23	disturbances	documenting
205:12 212:24	26:11 96:23	190:2 196:14,	325:19	345:14
	163:7 184:2	17 203:13	diversion	
	219:2, 8	204:4, 5, 10	149:19	

Protected Information - Benjamin Lebwohl, M.D., M.S.

Documents	12, 17, 17, 22	338:5 352:4	89:23 102:24	14, 16
8:9 11:12, 20	88:5, 18 89:2,	367:5 369:6	129:11 137:2	EGDs 264:5
12:7 16:15	12 93:23	Drug-induced	141:1 173:3, 4	Eisenhower
84:24 91:18	102:5, 15, 17,	135:12 136:15	178:11 179:11	2:3
95:17 136:7	20, 21 103:8,	137:20 154:18	203:16 219:8	either 30:14
297:13, 19	18, 23 128:12	247:22	239:2 250:7	35:11, 13 67:3
298:2, 6 299:8,	164:5, 9, 16, 24	drug-related	253:10 260:18	85:12 100:3
9, 11, 18, 21	184:21 185:15	306:11	263:7 278:21	113:12 130:2
300:3, 13, 15,	187:7, 22	drugs 251:21	294:13 296:23	132:21 137:6
22 301:9, 13,	198:23 200:2	252:6 260:7	313:24 367:7	138:24 139:1
23 302:11	202:13, 15	294:14, 16	368:14 371:12	145:23 154:15
340:23 374:19	204:1, 2	306:4 323:1	373:14 383:23	170:15 184:11
379:23 380:19	214:15, 19, 19	338:4, 5 359:5	earliest 313:21	187:11 192:11,
dogmatic	215:3, 13, 20,	due 37:16	early 30:5, 8	24 195:16
175:19	20, 24 216:1	50:4 71:4	32:3 34:6	196:6 209:10
doing 24:2	263:3, 3 271:4,	73:9 109:1, 4	72:4 153:23	218:20 230:13
39:7 98:15	5, 20 324:5, 6	111:6 119:5	178:9 214:20	237:23 238:3
139:4, 5	332:18 333:2,	122:17, 20	239:4 359:17	239:23 243:5
189:10 207:7	24 349:2, 23	177:19 195:9	easier 105:16,	245:1 246:22
253:21 291:9,	358:6	228:23 247:23	24	251:24
10, 21 297:2	dramatic	252:23 283:16	easy 16:9	elected 281:11
333:18 366:10	187:1 197:3	285:9 364:2	104:5 304:9,	electronic
domain 50:23	289:3	duly 385:5	12	196:6
57:23	draw 47:1	duodenal 18:2	eat 272:16	elements
Donald 80:22	145:24	120:12 273:3	eating 189:9	306:17
dosage 223:23	drawer 240:2	278:10	197:16 290:8	elevated
224:2 258:13	drawn-out	Duodenitis	editor 231:24	290:11
dosages 223:3	285:5	96:18	editorial 62:18	elicit 352:16
dose 221:20,	DRINKER	Duodenitis,	108:24 152:15	E-Mail 7:3
22 222:14, 18,	2:12, 17	153:13	effect 66:23	311:24 318:16
20 223:18	drip 294:15	duplicate	67:4 169:5	346:1
224:8 329:12	Drive 2:18	346:16	239:17 268:5	e-mails 30:13
dose-response	Drs 12:14	duplicates	284:17 303:4	embarking
222:4 223:21,	drug 12:15	346:20	306:11 325:18	293:1
24 224:12, 15,	23:18, 24 78:6	durability	374:4, 7	emerging
17	163:1 182:20,	250:9	effective 175:9	230:1 244:24
doses 175:21,	21 221:8, 14	durable 245:24	effects 58:18	emphasize
24 221:17	229:8 260:4	duration 66:2	151:20 176:20	150:13
224:10 293:19	284:16 288:5,	73:7 151:5	192:15, 16	employ 355:3
dosing 223:4	7, 8, 10, 13, 19	221:23 287:11,	233:4 304:8,	employed
224:12, 13	292:11, 12, 15,	17, 22 288:4,	11 306:4	299:15 317:17
double-check	23, 24 293:9,	10 293:4, 5	322:16 323:1	355:1
96:4 212:22	24 294:7, 18,	295:13, 17, 20	324:15, 15, 19	employees
doubt 329:5	24 295:15	330:24 331:4	325:2 373:24	298:20
DQ8 211:18	301:3 304:8,	332:11 367:18	efficacy 148:15	employing
Dr 5:8 9:14	11, 17 315:20	durations	effort 205:6	355:7
13:2 22:19	318:1 325:1	295:18	efforts 382:24	encapsulations
28:15 48:10	330:7, 24	< E >	EGD 157:15	306:2
53:2, 17 59:12	331:4, 11, 15,	earlier 24:16	263:15, 20, 24	encounter
61:19 85:20,	22 332:11	28:19 52:7	264:22 265:2,	69:4 111:10
24 86:19 87:3,				171:17

Protected Information - Benjamin Lebwohl, M.D., M.S.

encountered 108:11 300:10	12 34:1 47:7 48:14 49:9	23 175:15 176:19 177:22	138:12 146:15 154:21	equal 259:24 260:11
encountering 128:14 244:24	50:17 53:21 54:7 55:22	178:6 179:1 180:18 183:23	entire 68:17 321:18 327:12	esophagogastro duodenoscopy 157:15
encouragement 197:13	61:13, 22 62:2, 2, 5, 9, 13, 17,	187:15 191:4 203:3 210:24	378:15 entirely 187:11, 12	especially 93:5 101:7 116:14
endeavor 316:5	23 63:3, 9, 13, 21 64:4, 7	214:3, 17 216:24 220:9,	223:20 348:19 entities 230:1	229:24 327:3 ESQUIRE 2:3,
ended 142:19 189:6 196:16 197:16	65:1, 12, 18 67:14 68:19 69:9, 12, 18, 21	16 221:19 222:9, 19, 22, 23, 24 223:3, 9,	Entitled 5:5 88:15	7, 12, 17 3:2 essential 167:18 260:8
endoscope 239:11	70:2, 4 71:1, 8, 15, 20 72:18	13, 16 224:4, 7, 9 228:11, 12,	entity 33:8 61:5 72:17	essentially 62:16 224:15
Endoscopic 6:1 140:21 262:19	73:12 74:2, 7, 9, 12, 24 76:6, 8 77:24 87:5	23 232:3, 18 239:5 246:15	73:3 101:12 124:17 126:18	establish 165:19, 24
Endoscopy 18:5 120:16, 20, 22, 24	100:5, 7, 8, 9, 10, 11, 12, 13, 24 101:17	251:14, 19, 23 252:9, 12, 18, 20 253:3, 4, 5	190:22 252:21 298:13 362:4 372:22 373:2	166:9, 13 172:9 established 75:1 77:24
121:4, 14, 15 122:1 123:6 239:19 264:11, 14 265:12	103:9 107:24 108:9, 10, 16 109:1, 18 110:11 111:5, 22 112:2	254:17 256:1, 18 257:2, 4, 7, 15 262:4	382:3 entry 42:17 enumerate 226:21	92:2 142:24 143:6 146:11 217:1 257:16 258:15
267:24 269:20 endoscopy, 267:20	113:12 115:2 116:9, 12, 20, 21 117:7	268:3 269:3 270:6 278:23 279:4, 13, 18	82:17 90:15 226:7 enumerating 111:24	establishes 47:5 60:12 estimation 330:23
endpoints 356:9	118:22 119:2, 23 120:5, 10	280:14, 18, 22 287:6 289:1 296:17 297:14, 22 299:19	enumeration 226:19 environmental 65:17	et 5:17, 21 6:8 18:1 91:19 110:15
ends 114:14 engage 43:5, 13 316:8, 10	121:13, 20 122:24 123:21 124:4, 20	300:6 310:8 315:14 316:7 323:6 325:21	epidemiologic 50:22 75:16	115:22, 24 146:15 201:1 256:2 271:13
engaged 23:12, 14 27:8 33:3 61:15 302:23	126:24 127:4, 10 128:2, 15	332:16 333:1 344:19 345:4 348:21 350:15, 22 351:1, 7	epidemiological 50:13 58:23 59:6 87:10	281:13 282:7 287:10 371:6 375:3 377:22
engagement 31:17	131:6 133:21 135:12, 20 136:2, 21	352:10 355:16, 17, 24 358:9, 10 360:18	242:4 epidemiologist 59:2	ethical 26:4 evaluate 18:3 265:18
engine 98:11 ensuing 186:3	137:11 138:2 141:7 143:17 146:7, 20, 23	361:24 362:12, 13, 16, 21 363:21 364:2,	epidemiologists 151:7 epidemiology 17:1, 3 58:21,	evaluated 214:16 378:7 evaluates 233:21
ensure 259:24 entails 175:10	147:4 150:20 152:1 154:18 156:1, 21	366:9 367:4 368:23 370:13 371:10 372:23	22 59:1 68:12 92:3 epithelium 127:15	evaluation 78:1 79:9 144:10 145:8
enter 355:7 enteric 127:16 Enteritis 362:10, 12	157:1, 6 162:6 165:20 166:2, 11, 23 167:7	374:12 375:4, 6, 15 379:9 381:22 enteropathy, 132:11 135:16	Epocrates 325:4	184:14 265:1, 2, 3
Enterocolitis 362:15	168:13 169:7, 18, 19, 23 170:9 171:23			
enterocyte 259:15 260:5	172:11, 22 173:24 174:15,			
Enteropathy 5:11, 20 20:16, 22 31:1 33:9,				

Protected Information - Benjamin Lebwohl, M.D., M.S.

Event 6:21 149:13 230:10 240:20 241:7 268:16 279:20 283:3 286:18 309:23 310:5 315:20 318:1 320:19 334:19 337:17 339:15 340:1, 22 345:14 354:6, 13, 15 355:14, 18 356:16, 17 358:8 382:6 events 148:18 149:15 230:7, 12, 18 231:6, 12, 17 233:13 303:11 322:8 354:24 359:4 380:21 eventually 96:19 everybody 384:3 evidence 47:4 60:11, 21 96:18 103:3 111:4 114:16 147:13, 14, 21 149:16 151:17 153:13 166:20 168:1 174:9 206:10 209:1, 21 227:16 251:3 256:11 279:3 318:7 329:7 343:6 369:2, 4, 9, 10, 11 373:20 378:8, 11 evidence-based 16:24 150:4 evidenced 180:21 evinced 218:13 325:24 evolved 27:22 exact 187:8 196:2 225:11 315:2 346:20	exactly 114:10 322:21 327:18 EXAMINATIO N 9:11 257:22 366:23 examine 238:16 examined 9:9 examining 316:20 example 17:2, 20, 21, 24 18:7 19:6, 13 20:13 22:10 25:3 53:3 69:1 72:9 83:20 91:24 93:6, 19 94:19 96:9, 14 97:22 98:5 103:17 112:11 119:1, 4 125:16, 17 126:6 143:14 157:12 167:19 168:17, 20 170:20 171:1, 8 211:16 223:18 226:3 227:11 230:6 242:11 243:11 245:16 254:23 280:19 283:10 285:6 295:17 304:19 325:2 333:8 339:19 345:10, 13 355:22, 23 356:2 361:4 365:19 371:11, 14, 19 374:2 380:3 examples 99:16 exceeded 222:9 exception 24:2 191:6 excerpt 335:19 336:3 Excerpts 6:16 335:11 338:16	exchange 338:15 excluded 245:17 exclusion 247:16 256:22 exclusively 169:24 excused 384:4 exemplify 345:4 exercise 113:1 126:16 exercising 333:18 exhaust 131:3 exhausted 97:14 exhaustive 225:15 254:20 Exhibit 6:10, 14, 24 7:5 9:2 11:2, 8 14:8, 18 28:7, 9, 16 34:11, 19 35:3, 3, 8, 22 36:5, 12, 13, 15 37:18 38:1, 9 39:1 40:4 42:15 43:19 80:2 83:23 84:17, 17 85:5 88:14, 24 89:9 90:16, 23 91:1, 10 92:5 161:8 178:23 179:7 200:20 255:22 256:7, 17 262:12, 14 263:1 271:7 307:8, 10, 17, 17 308:5, 5, 10, 21 318:6 320:2, 4, 11 335:10, 18 339:23 340:3, 9, 13 343:5 345:21, 24 346:4 357:21, 24	exhibited 274:18 276:18 exhibits 34:22 35:2 36:8 44:1 300:13 301:10 existed 95:15 existence 61:12 62:17 existing 33:17 exists 114:12 expect 380:8 expensive 64:1 experience 16:22, 23 72:11 73:4 90:1, 12 95:10 114:22 125:9 183:8 184:6 200:3 279:14 288:24 289:6 296:15 323:11 experienced 284:4 322:7 341:18 experiment 55:20 57:13, 23 226:23, 24 227:4 experimental 260:14 experimentatio n 53:18 experiments 50:10, 13, 23 51:13, 16, 22, 24 52:23 62:11 258:18 259:22 261:5, 20 expert 1:7 4:21 12:14 13:3 22:20, 23 23:2, 4, 22 25:17 27:8, 10, 17, 20 29:13 30:19, 24 31:7, 12, 19, 21 32:4 33:2 34:12 61:8 62:20 86:10 87:16	90:18 91:13 98:22 99:20 100:3 163:15 275:18 302:24 expertise 29:20 30:2 77:1 87:4 experts 20:21 163:20 explain 10:3 69:11 107:3, 5, 6 372:2 explained 103:1 255:7 explaining 235:5 explanation 10:17 74:10 79:13 112:7 127:13 216:10 338:2 372:24 explanations 334:8 344:6 explicating 225:21 explication 220:6 explicit 103:12 117:15 explicitly 84:23 93:10 94:1 132:22 258:1 327:9 334:3 explore 143:16 exposed 69:5 79:5 223:10 248:22, 23 249:3 266:14 276:23 277:16 281:1 exposure 67:10 114:18 145:22 158:3 229:9 254:22 267:5 280:4 378:20 expounded 219:18 express 270:24 367:24
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protected Information - Benjamin Lebwohl, M.D., M.S.

expression	216:1	126:22 128:1	field 62:20	172:2 189:18
132:10 361:13	failure 383:15	185:1 274:12	265:11 382:16	190:3 209:14
extensive	Fair 10:4	276:5 279:8,	fight 106:7	finishes 318:19
296:15	18:18, 21 21:4	10, 10, 15, 18,	figure 264:17,	firm 145:24
extensively	30:20 112:22	19 349:10	18 287:21	first 9:22
261:13 262:6	142:11 152:22	361:5, 6, 7	296:2	20:24 26:5
extent 51:12	188:19 208:10	362:21 364:5,	figured 190:14	27:12, 15 29:8,
86:23 87:21	305:24	6, 18	191:3 294:3	24 36:16
215:17 260:1	fairly 24:22	features 50:18	files 24:23	42:16, 17, 21,
291:23 303:7	96:1 164:23	71:24 74:10	filings 298:21	24 43:10 57:5
305:20 380:6	349:20	100:20, 20, 21	filled 68:17	65:21 66:17
extremely	fall 314:1	101:1, 5, 9	final 37:14	68:5, 5 70:11,
259:16	383:6	116:20 121:1	274:17	14 77:11
eye 123:6, 11	familiar 59:20	124:3, 3 141:3,	finally 72:16	80:18 82:19
eyes 185:23	72:17 73:3	4 252:10, 11	find 20:20	93:6 97:21
	225:16 230:24	253:8 274:19	22:5 56:19	106:11, 15
< F >	261:16 298:14	275:15, 20	62:18 105:21	107:15 111:16
facing 37:8	305:3 322:15	276:2, 15, 19,	106:17 138:18	113:22 129:7,
fact 34:7 61:5	323:8	21 277:18	140:8 144:15	10, 18 138:18
65:8, 14 66:21	familiarity	278:22 279:1,	159:22, 23	147:11 152:13
78:12 117:11	59:23	12, 23 280:1,	173:8 238:21	163:9 184:13,
121:24 122:21	family 180:22	12 366:9	239:22 272:10	15, 20 190:7
146:18 152:24	188:23 189:13,	February 1:7	295:19 298:16	202:13, 15
156:24 166:22	15, 23	385:15	325:4 356:17	203:7 213:6,
167:7 173:24	famous 375:20	Fecal 362:20,	363:7 366:3	13, 14 216:21
178:18 181:20	far 42:23	24 363:16, 17	finding 54:4	224:22 254:20
184:24 189:4	66:21 202:18	feces 361:5, 7	122:2 144:12	263:10 267:11
195:8, 9 203:9	220:4 222:9,	Federally 1:18	145:6 233:22	273:20 297:17
246:10 248:21	13 236:6	385:14	238:12 274:3	312:18 313:7
251:6 261:24	239:22 265:10	feel 169:8	372:1	315:4 319:4
270:7, 9	325:6 381:6	293:24	findings	320:23 325:24
284:17 323:13	fashion 204:12	feeling 255:10	123:19 214:20	330:12 334:16
324:7, 23	fat 117:14	303:10	215:21 255:8,	339:13 340:15
326:10 328:24	119:6, 14	feels 169:15	12 267:17	350:16, 17
329:22, 24	fatal 284:16	Feldman	278:9 369:4	358:17, 24
334:5 341:22	fate 264:3	80:19 84:5	finds 143:2	359:24 364:22
342:6 343:23	fatty 119:1	323:15 324:5,	fine 46:6, 23	371:1 381:7,
344:2, 18	fax 1:22	6 332:13, 18	76:23 92:18	11
362:18 371:4	FDA 12:15	334:1	104:3, 13	fit 113:21
373:7, 19, 22	161:12 162:6	felt 87:8	106:1 107:13	184:12 313:22
377:11 379:14	228:2, 4, 18	198:6 293:15	120:3 130:15	fits 372:4
factor 250:23	229:19 298:22	304:7	139:6 169:15	Five 137:11
254:13	299:12 303:4,	female 345:17	198:16 208:5,	334:16
factors 65:17	9 304:4	347:1, 19	18 238:5	fivefold 159:4,
68:21, 24	356:15, 19, 20,	fences 239:16	249:14 253:22	11
73:10 225:4	21 357:4	fewer 158:2	339:1 364:9	five-minute
334:21 337:14,	359:4, 7	239:22	finish 67:17	254:2
21 338:9	FDA's 228:14	fibrillation	94:21 207:17	flag 262:10
faculty 58:24	feature 116:22,	322:10 327:6,	finished	flaw 343:2
failed 215:4	23 117:1, 2	8	101:23 106:24	Floor 2:3
	120:9 124:14		130:17 137:8	

Protected Information - Benjamin Lebwohl, M.D., M.S.

Florham 2:18	forceful	foundation	182:16 184:20	149:20 163:16
florid 225:20	112:11, 16, 20	18:11 19:11	199:21 216:21	190:13 191:6
flower 270:10	fore 94:2	215:15 216:5	224:22 315:24	225:7 242:3
focus 59:10	306:12	217:11 233:16	319:4 339:13	270:3 272:21
143:13 146:13	forefront 98:6	236:3, 11	340:15	299:13, 24
359:20	foregoing	249:24 298:24	fully 90:10	327:23 354:9,
focused 17:8	385:17	299:4 342:21	106:23 215:9	16 357:2, 13
51:21 87:9	Forgive 369:11	360:12 380:15	355:21	381:6
268:18	form 16:5	382:18	function 30:19	generalize 95:3
Focusing	124:9 181:13,	foundational	functioning	generalized
36:15 144:6	24 226:14	297:19 300:3	32:4	315:6
275:11 313:10	302:7 305:12	foundations	further 46:1	generally
folks 129:2	324:7 343:4	357:11	76:16 94:4	26:15 147:12
141:4 189:13	370:20 371:17	four 113:20,	96:19 107:3	148:1 211:22
190:6, 8	373:5 374:23	22 130:20	113:5 150:11	240:9 251:23
191:10 193:6	379:11 380:15	163:23 164:2	182:8 200:11	277:16 327:5
201:16 214:1	381:2 382:18	273:10 278:3	218:17, 17	generate
266:5 274:21	formal 13:13	283:19 334:15	219:18 220:6	24:17, 18
275:14, 16	101:14 117:19	345:9	246:21 251:11	25:11 36:19
276:12 277:15	187:14 188:3	fourth 273:15	338:1 344:18	92:11 164:15
285:24 350:7	196:4, 21	frankly 63:21	future 116:13	316:17 328:17
follow 103:20	356:13	120:10 148:13	146:13	354:12 355:17
104:5 105:17	formally 27:10	196:7 197:1	< G >	generated
151:12, 22	forming 378:9	284:15 357:6	gain 127:20	16:1 25:12
186:17 353:9	formulate	fraught 149:4	game 68:15, 16	34:21 93:2
374:5	77:12	189:19	gastroenteritis	95:22 98:20
followed 24:24	formulating	FREEMAN	69:6	137:5 310:3
25:1 151:8	91:19 317:2	2:1	gastroenterolog	357:8 367:12
180:1 251:24	forth 19:8	frequent	ist 58:4, 5	generates
314:6, 17	21:15 37:1	58:10 178:19	368:15	301:4
356:3	48:1 62:1	363:1	gastroenterolog	generating
following	87:14 170:12	frequently	ists 72:14	25:10 40:14,
110:24 283:14	186:8 209:18	58:8 191:19	gastroenterolog	20, 24 41:9
284:8 383:5	250:3 267:11	241:14 304:20	y 18:5 57:10	42:1, 7 45:13
follow-on 78:9	270:1, 11, 14	314:24	136:17	93:9 163:20
268:2	282:21 293:6	friendly	gastroenteropat	generation
follows 9:9	332:19	305:18	hy 364:5	40:17 41:19
173:14	forthcoming	front 36:4		164:17
follow-up	41:18	38:8, 24 40:3		generic 148:3
151:5 167:3	fortunate	83:23 88:23	Gastrointestinal	149:9 150:3
173:20 179:18,	151:5	103:7 105:13	18:4 120:15	211:14 242:6
23 206:23	forward 140:2	179:14 256:6,	349:9 350:9	325:18 373:20
218:21, 21	found 56:12	17 262:24	363:2, 18	Generically
220:14 281:23	87:2, 7 88:4	272:24 291:18	364:8	354:4
287:2 321:19	99:15 120:22	307:17 327:14	gender 269:21	genes 211:19
377:12, 19	145:21 157:4,	340:13 357:3	General 3:2	genetic 212:3
378:2	23 200:5	frustrated	4:24 28:5	gentlemen 80:8
Fonseka	214:7 239:17	304:5	32:13 34:14	getting 52:13
133:20 154:13	240:11 247:21	fuel 316:4	39:10 44:2, 3,	72:7 111:7
foolish 252:24	261:8, 21	full 20:19	11, 24 78:21	119:24 120:12
	277:19 288:2	147:11 180:16	134:16 148:22	167:22 185:23

Protected Information - Benjamin Lebwohl, M.D., M.S.

193:4 195:2, 8 248:4 290:21 357:5 GI 114:23 141:12, 14 143:9 190:6 315:1, 3, 6 325:18 give 17:19, 21 30:6 80:8 96:8 106:16 107:5 132:13 134:13 190:10, 22 196:2 203:4 219:4 272:9 283:10 319:22 321:1 330:15, 22 332:10 334:24 341:4 348:5 372:23 given 64:1 103:6 113:3, 17 199:23 200:1 210:22 222:14 249:4 269:2 281:1, 12 295:17 298:12 311:11 356:17, 20 362:16 363:3 364:16, 22 372:5 381:21 385:6 gives 139:7 glad 163:13 353:8 glancing 272:7 glean 242:22 gleaned 151:18 global 334:17 globally 349:10 gluten 68:1, 5, 10 73:11 78:22 79:5, 5 168:6, 11, 15 169:2, 14 176:14, 16 180:22 189:9 197:7, 9, 16	255:10 290:8 296:18 343:22 361:23 gluten-containi ng 78:15 gluten-free 167:22 168:21 211:13 212:7 281:2, 5, 10, 14 290:10 gluten-induced 168:13 169:7 go 26:4 46:21 73:14 78:18 79:24 81:19, 23 86:13 93:17 94:16, 20 105:22 106:6 107:14 108:4 115:18 118:10 132:20 137:9 139:15 160:20 178:4 182:14 207:21 208:4 212:21 214:21 236:15 255:16 259:1 266:12 268:13 277:23 292:17 303:11 304:14 305:8 316:23 319:10 325:12 336:8 339:1 353:15 361:1 370:15, 24 372:15 376:8 goal 342:5 goes 75:2 159:2 167:23 362:7 364:7 369:1, 13 going 13:17 17:6 18:16 26:10 28:4 32:16 33:10 45:24 49:14 72:13 83:22 86:13 105:12, 19, 20 106:10, 22 126:13 139:16 140:2	157:20 188:6 192:18 196:9 199:3 208:12, 13, 19 219:3 248:10 250:16 252:3 255:17 271:3 277:22 302:19 306:20 307:3 324:14 326:16 327:11, 12 338:21 343:23 345:20 346:17 353:6 357:20 358:15 366:13 372:8, 15 383:4, 7, 11 gold 148:9 GOLKOW 1:22 Good 9:14, 15 39:16 105:3 140:1, 4 195:23 262:8 264:17 294:5 301:22 382:4 gotta 79:23 318:14, 16, 19 gotten 195:14 gradient 224:15 gradually 285:12 granted 95:6 99:11 108:7 132:8 138:21 139:1 granting 25:21 grave 151:9 great 73:4 118:16 145:12 363:10 Green 57:7 109:13 110:5 153:11 184:21 187:7, 23 198:2 202:16 204:2 214:19 215:3, 20, 24 263:4 271:5 349:2, 23	Greywoode 6:3 140:18 145:4 146:2, 3 156:9, 10, 13, 15, 17, 18 236:21, 23 237:21 238:15 262:12, 20 263:2 371:22 378:23 group 115:3 129:1 145:23 178:18 183:11, 15 201:23 202:13 203:21 204:20 220:22 240:9 246:14 249:1, 2 267:6 273:3, 6, 9, 12, 14, 15 274:10 275:7, 9, 24 276:6, 22 381:15 groups 184:1 244:23 247:3 249:6, 10 273:10 274:23 grow 168:24 guess 78:8 121:23 199:20 235:18 334:14 368:1 383:20 Gujral 98:17 gut 69:3 127:15 < H > habit 361:9, 10, 11 half 70:15 223:18 half-life 176:2, 21 294:23 Haller 233:3 halted 230:16 Hammoudi 137:24 155:13, 14 hand 28:3 48:8 149:12	150:15 308:21 347:6 handed 12:18 28:15 34:18 179:6 handful 344:14 hanging 320:10 335:17 handled 372:14 handy 305:18 Hang 321:7 haplotype 211:18 happen 49:14 68:6 315:7 351:8 363:24 happened 246:4, 17 281:23 282:4, 10, 18 308:15 315:3 338:15 351:16 381:6, 11 happening 230:10 happens 69:7 235:19 247:19 314:24 happy 64:19 hard 175:19 280:6 harder 251:15 hard-pressed 171:7 harmed 60:7 Hartranft 138:9 155:17 Hasebe 6:19 81:6, 8 334:17 335:13, 20 337:20 338:1 Hasebe's 336:23 hat 357:4 HCT 191:23 341:2 head 10:12 188:18 190:12 334:17 366:4
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protected Information - Benjamin Lebwohl, M.D., M.S.

heading 182:15 226:17 227:4 297:13 headlined 138:22 heads 129:15 188:1 heal 375:12 healing 183:5 296:14, 20 375:10 Health 59:2 161:12 162:9 164:6 healthcare 151:10 171:13 hear 311:22 324:23 heard 185:15, 19 196:22 303:8 hearing 184:21 heart 101:6, 8, 10 height 123:24 HeLa 261:16 held 1:15 help 45:19 163:13 198:7 212:24 helped 272:14 382:24 helpful 60:2, 3 87:7 88:6 91:21, 23 98:2 119:18 152:4 242:12 261:21 266:11 290:6 297:20 300:4 302:15 356:1 364:12 373:2, 12, 19 382:14 383:16 hero 164:6 herring 328:1 Herve 81:16 86:6 353:21 hesitant 121:17 124:18 142:1 144:18	190:10 197:7 285:17 hesitate 188:17 hesitates 268:10 Hey 39:18 Hideki 81:12 84:11 hierarchy 147:13, 20 148:1, 2, 3, 5, 13, 22 149:10, 16, 21, 23 150:3 372:18 high 285:11, 12 351:4 374:3 higher 114:15 221:18 223:2 224:3 229:14 high-impact 370:1 highly 154:11 high-reputation 370:2 Hill 224:16, 18, 24 225:5, 9, 17, 21, 23 226:4, 6, 17, 20 227:1, 9 241:9, 13 254:11 378:6 Hinman 80:22 81:5 85:24 hint 98:2 histologic 50:7, 19, 21 51:10 53:23 54:3 69:23 74:3, 5 96:17 111:2 153:13 167:12 168:1 192:20 255:12 257:5 290:4, 22 291:1, 5 histological 74:3 100:19 255:8 296:5 Histologically 74:8 245:19	280:10 291:11, 22 292:2 histology 6:5 53:7 109:24 237:12 271:9 290:13 292:6 histopathologic 88:8 histopathologic al 87:6 253:14 273:24 274:3 history 180:23 188:23 189:13, 15, 23 193:17 257:23 283:19 322:10 326:11 HLA-DQ2 211:18 Ho 81:24 86:3 307:20 308:22 309:1 333:8 hoc 62:10 374:13 hold 174:6 233:19 holiday 287:22 288:5, 8, 9, 10, 19 289:7, 19, 22 292:11, 12, 16, 24, 24 293:9 294:8, 21 295:15, 15 330:7, 24 331:4, 11, 16, 23 332:11 holidays 288:14 homogeneous 129:17, 17 honest 171:11 honestly 25:19 54:19 122:12 hoops 199:6 hope 26:6 265:21 hopefully 301:5	Ho's 308:6, 11, 13 hospitalization 116:3 285:8 334:23 hospitalizations 293:18 337:16 382:1 hospitalized 284:6 285:7 hour 43:21 372:15 huge 239:13 268:24 269:16 human 60:6 259:16 humans 59:19 hundred 157:18 191:5 hung 119:24 Hutless 164:3 hydrochlorothi azide 191:22 hypermotility 363:18 hypotension 284:7 hypothesis 145:7, 18 270:15 hypothesized 66:9 hypothetical 70:11 < I > i.e 192:24 332:8 iceberg 143:19 239:9 360:8, 15 363:7 idea 61:11 208:15 267:8 ideal 100:23 260:10 ideally 304:7 ideas 91:22 identical 194:8 221:3	259:3, 21 260:8 identification 9:5 14:14 28:12 34:15 36:1 38:5 88:20 179:3 201:2 256:3 262:21 271:14 307:13 320:7 335:14 340:6 346:7 358:2 identified 15:19 19:6 79:15 83:16 84:10, 21 86:19 90:14 92:5 237:22 255:9 288:9 350:17 identifies 91:11 identify 58:3 80:15, 19, 22 81:12 84:4 86:9 96:6 105:5 106:11 107:2 113:19 114:1 136:24 152:6 161:10 163:14 225:14 226:9 282:22 283:5, 6 287:1 319:5 338:10 354:14, 24 355:9, 12 360:7 370:17, 23 identifying 372:21 ill 142:1 166:17 169:3, 4 183:1 195:11, 16 255:10 284:18, 22 327:3 ill-defined 124:17 illness 285:5 288:21 296:6 323:19 324:2
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protected Information - Benjamin Lebwohl, M.D., M.S.

325:16 332:15	implicitly	295:3 296:21	11 247:6	indication
334:7	318:2	369:5 375:24	248:14 257:14	265:11 325:14
illustrated	implied	376:5, 19	313:22 348:15	327:16 331:3
288:11	132:23 133:10,	377:6	inclusive	indirectly
illustrative	16, 17, 18	improvements	247:13 360:22	306:18
99:7 287:20	imply 139:2, 2,	187:2	incomplete	individual
345:3	10	inaccurate	80:6 309:21	70:2, 4, 24
imagine 142:5,	implying 282:7	160:17 181:10,	314:9	71:6, 14 120:5
17 169:11	import 139:12	17	inconsistent	149:4, 8 223:8,
301:1, 6	importance	inaccurately	313:12	10 302:1
imaging 97:18	149:17	272:9	incontinence	individuals
immediate	important	inadequately	362:20	62:22 63:4, 12
16:20	241:11 259:23	101:18	incorporate	69:13, 19, 21
immediately	292:1 301:11,	inadvertent	306:16	70:7 73:13
21:11 344:5,	15 302:3	163:9	incorporates	108:17 117:9
20	343:16 352:15,	incidence 64:3	369:22	120:23 157:23
immune 67:5	19 360:11	270:6 353:3	increase	163:23 178:14
69:4 259:11	364:15 365:4	incident 71:1	159:11 224:2	260:6
Immunopathog	372:3	include 15:18	increased	individual's
enesis 5:18	imposed	16:17 17:16	93:20 159:4	375:11
135:14 154:20	281:15	36:23 154:22	224:2 363:16	induce 108:20
254:16 255:24	impractical	184:7 247:11	increasing	115:13 127:18
immunosuppres	151:17	248:11 257:23	221:17	induce, 103:13
sant 193:16	impression	304:21 364:7,	increasingly	induced
246:3	178:20 189:2	10 366:10	61:6 64:3	116:12 138:8
immunosuppres	316:21 373:15	369:16, 24	132:7	induces 50:20
sants 192:9,	imprimatur	375:11 383:7	INDEX 8:2	inducing 224:6
11 193:6	234:4	included 75:3,	104:12	induction
194:13 205:23	improve 78:5	4 77:23 78:2	indicate 10:2	67:13
206:2, 6, 19	183:11, 16, 18	79:9 85:1	59:13 146:10	infarction
248:24 249:5	215:4 216:2	93:15 99:18	206:4 221:24	101:11
immunosuppres	improved	186:10 206:7	274:17 278:14	infection 171:2
sion 193:2	182:21 200:4	225:23, 24	287:11, 16	infer 331:9
194:5 243:10,	202:4 206:20	256:24 257:17	311:12 326:20	inflammation
21 245:7	221:8, 14	298:21 300:13,	327:23 330:6	59:14 364:8
246:12, 19	245:18 283:14	14 353:2, 19	341:17 352:23	inflammatory
247:1, 4, 15	293:15 377:20	368:10 369:18	indicated	177:19
248:16, 19	improvement	includes 15:14	206:22 219:18	inform 185:24
immunosuppres	111:2 167:24	50:18 283:4	240:6 343:12	informal 204:7
sion's 250:6	175:13 176:7	287:8 335:21	351:11 376:21	INFORMATIO
immunosuppres	177:1 193:19	336:4 369:3	indicates	N 1:7 88:7
sive 377:21	195:6, 22	including 24:5	61:21 146:16	91:12 110:17
impact 262:3	205:21 206:1,	72:14 87:16	184:10 211:11,	199:23 200:1
impacted	5, 10 209:2, 21	89:10 91:13	15 218:18	242:12 297:20
157:11	210:7 216:9	121:2 253:13	287:21 310:18	300:4 321:20,
implicated	218:14, 23	305:14 349:19	330:1, 11, 13	24 329:16, 19,
325:20	220:11 243:18	inclusion	334:8	21 330:1
implication	247:14, 15	77:19, 22	Indicating	380:1, 7, 9
284:15	284:5 289:2,	128:9, 10	81:1 133:6	381:17 382:8
implications	23 290:12, 13,	183:15 184:12	220:8 347:12	informed
268:11	17 293:11	245:14 246:9,	376:12, 13	75:20 114:20

Protected Information - Benjamin Lebwohl, M.D., M.S.

infusion 294:15	73:1 199:1	internally 351:20 380:7	investigate 49:6 62:8, 13	150:14 160:16
ingredients 192:1	instruct 46:5	international 116:10	63:20 64:7	199:8 243:15
initial 93:16	instructions 9:22	interobserver 125:5	169:5	244:11 264:7,
106:9 110:9	insufficiency 383:14	interpret 133:5	investigated 50:2 53:23	23 285:13
122:5 133:5	insufficient 123:17 126:8	interpretation 128:21 159:5,	investigation 75:4 78:2	306:10 360:23
178:20 183:20	intend 47:14,	6 183:14, 21,	257:17, 18	362:11 370:5
185:16 212:21	24 48:10	24 184:4	investigations 79:10	issued 11:4
233:22 247:11	intended 239:24 286:2	202:2 218:11	investigator 164:10	it , 377:22
248:11 314:2	intentional 342:6	328:14	investigators 115:4 244:23	item 133:23
349:15	intentionally 342:1, 4	interpreted 125:11	246:13 258:22	163:6
initially 27:8	interacted 58:15	interprets 332:22	259:20 286:1	items 11:21
33:6 74:13, 20	interactions 58:10 304:17	interrupt 175:4 207:3,	invite 161:17	12:1 15:14, 18
75:8, 14, 21	interchangeabil ity 212:11	16 342:22	Invoice 4:21	90:15 91:12
93:2 104:9	interchangeable 362:2	interval 158:5,	28:10, 20 29:1	358:18, 19, 23
174:13 203:10	interchangeably 252:4	14, 17 159:1, 7	42:16 82:19,	iteration 36:17
212:8, 17	interest 339:8	intervention 171:4, 19	23 83:7, 17, 21	It'll 105:24
213:18 214:5	353:12 382:15	230:15	84:2, 9, 17	106:1
224:23 228:24	383:4, 10	interventions 148:15	85:5, 23	its 53:12
239:24 246:18	interested 32:22 144:1	interviews 264:16	invoiced 85:1	96:20 98:13
365:14	162:5 186:14	intestinal 50:7	Invoices 5:3	137:7 143:2
initiate 183:3	218:1 238:7	114:17 121:5	12:19, 21	146:17 228:5
initiated 287:13 294:7	267:4	134:6 231:12	28:18 38:3, 11	251:13, 13
initiating 367:5	interesting 74:17	233:4 262:7	39:2 40:5, 8,	252:10 275:6
initiation 315:11	intermittent 128:20 327:7	296:19 363:9,	12, 18, 22 41:5,	328:21 329:23
initiative 120:21	intermittently 71:11	11 364:9	17, 18 42:2	356:16 364:18
injured 127:15	Internal 107:17 136:6	368:23	82:17 83:11	
injury 23:19,	297:13, 18	intestinal-relate d 231:6, 17	85:19 86:5	< J >
24 119:4	298:1, 6, 19	233:13	involved 24:23	January 53:12
input 13:16	299:7, 18	intestine 59:15	25:22 56:13	97:23 332:2, 4
357:9	300:2, 15	123:5 261:8	167:10 202:22	Japan 334:18
inputs 317:6	368:17 370:4	262:2, 4	203:16, 20	Jeffrey 81:14
inside 129:15	374:18 379:23	intimately 21:1	236:1 284:18	JERSEY 1:2
356:19	380:9, 18, 22	introduce 202:21	involves 167:13, 15	2:4, 18
instance 132:20 141:21		introduced 68:6 327:19	257:22	JESSICA 2:17
174:8 222:3		introduction 108:22	involving 27:7	jessica.brennan
288:8 303:19		invariable 165:10	370:6	@dbr.com
333:8			iron 119:9, 11	2:19
instances 65:15, 20			121:2	Joe 187:24
66:18, 20			irrelevant 98:24	jogged 98:10
168:3 170:20			issue 26:16, 20,	joke 292:17
354:14			21 50:24	journal 18:5
institution			63:16 98:23	53:11 57:9
			114:6 149:11	136:16 154:12
				370:2, 3
				JS 1:6
				judgment 333:19
				Julian 93:19
				July 161:13
				339:16 340:23
				jump 208:14

Protected Information - Benjamin Lebwohl, M.D., M.S.

jumping 323:10	164:7 269:18 330:2 344:3	known 123:23 164:5 191:19	largest 276:20 277:12	Lebwohl-13 6:8 307:9
jury 76:18, 19	know 13:23 14:23 18:20	204:4 223:8, 15 252:21	lasted 288:14	Lebwohl-14 6:12 320:3
jury's 76:14	26:15 39:7 46:12 49:12	325:15 333:11 382:2	lasting 218:23	Lebwohl-15 6:16 335:11
< K >	54:12 55:4 64:2, 18 66:21	< L >	late 37:9, 10 42:8, 13 44:9 72:3	Lebwohl-16 6:19 339:24
Kaplan 1:16 2:7	67:18 68:23 70:10 71:22	label 126:19 211:22	latency 229:10	Lebwohl-17 7:3 346:1
KATZ 2:1	73:7 77:15 82:3 96:2	labeled 212:17 213:18 214:6	laugh 326:6	Lebwohl-18 7:7 358:1
keenly 186:16	118:5 119:6, 7 121:20 125:21	laboratory 69:23 253:15 290:4	law 1:15	Lebwohl-2 4:16 14:9
keep 10:11, 16 140:2 187:13	127:14, 19 144:7 145:15, 20 147:5	lack 64:24 177:21 215:14 216:4, 8	LAWYER'S 386:1	Lebwohl-3 4:21 28:10
188:12 317:19 363:8	150:24 157:19 158:6 169:22	217:10 233:15 236:2, 10	lay 352:11	Lebwohl-4 4:21 34:12
keeping 187:14 188:2	181:19 182:5 188:16 190:18, 20, 22 192:3, 5	249:23 251:15 298:23 299:3 377:12 378:2	layer 278:18	Lebwohl-5 5:1 35:23
195:1 363:22	194:2 196:18, 23 204:8	380:15 382:18	lead 120:15 315:18 353:9	Lebwohl-6 5:1 38:2
Ken 9:16 207:15	207:19 208:11, 13 213:21	leads 221:18 224:3	learn 202:7 270:4	Lebwohl-7 5:5 88:15
KENNETH 2:12	218:1 222:11 239:6, 10, 12	298:23 299:3 377:12 378:2 380:15 382:18	learned 17:4 21:3 123:4 202:20	Lebwohl-8 5:10 178:24
kenneth.murph y@dbr.com 2:15	257:10, 13 258:14, 23	lacks 110:16 Lagana 6:8 53:3, 17 86:10 96:14 102:4 110:3 112:18 131:18 153:5, 9, 10 237:2, 21 238:6 271:3, 13, 20	learning 64:3	Lebwohl-9 5:12 200:21
kept 188:21	259:10 269:2, 16, 24 279:5 288:18, 23	laid 370:6	leave 329:11	Lebwohl's 13:2
KESSLER 2:7 164:3, 5	291:13 295:18 296:4 312:2 317:22 326:18	language 111:14 370:5	LEBWOHL 1:15 4:5, 14, 19, 21, 23 5:4, 9 9:4, 7, 14 10:22 14:12 15:4 18:1 22:19 28:11, 15 34:13 38:3 48:10 59:12 61:20 88:19 89:2 103:8 108:23 109:13 110:5 112:19 131:15 153:10 164:24 198:23 333:3 358:7 385:8	Leffler 102:6 164:9, 17
Kessler's 102:15, 17	327:2 343:1 344:9 347:2 352:5, 7 353:12 357:1 362:16 364:16 372:8 381:9 382:11	land 230:11	learned 17:4 21:3 123:4 202:20	Leffler's 102:20
Kim 48:20 54:10 66:11 173:9 207:22 312:5	knowing 189:22	large 56:19 60:5 120:23 239:17 242:23 244:14 261:8, 15 262:2 301:2	learning 64:3	left 132:11 163:9 182:14 303:10 304:10 356:5 365:9
Kimberly 1:17 385:13	knowledge 63:18 64:24 95:5, 8 99:12 162:4 177:22 224:10 231:11 352:1, 9	largely 87:2 202:1	learned 17:4 21:3 123:4 202:20	legitimate 26:2 legs 254:5
kind 10:14 18:15 25:6 159:10 223:5 232:15 245:21 257:21 265:14 269:11, 14 285:3 325:7 326:10 345:3 354:17 360:18	known 123:23 164:5 191:19 204:4 223:8, 15 252:21 325:15 333:11 382:2	larger 305:22	learned 17:4 21:3 123:4 202:20	length 132:2 331:16, 21 lesions 138:3 lesser 93:21 122:8
kindly 270:17	known 123:23 164:5 191:19 204:4 223:8, 15 252:21 325:15 333:11 382:2		learned 17:4 21:3 123:4 202:20	Lethargic 126:5, 7, 9
kinds 359:23	known 123:23 164:5 191:19 204:4 223:8, 15 252:21 325:15 333:11 382:2		learned 17:4 21:3 123:4 202:20	
kitchens 197:11	known 123:23 164:5 191:19 204:4 223:8, 15 252:21 325:15 333:11 382:2		learned 17:4 21:3 123:4 202:20	
Klug 3:2	known 123:23 164:5 191:19 204:4 223:8, 15 252:21 325:15 333:11 382:2		learned 17:4 21:3 123:4 202:20	
knew 33:17 73:2 97:15	known 123:23 164:5 191:19 204:4 223:8, 15 252:21 325:15 333:11 382:2		learned 17:4 21:3 123:4 202:20	